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Abstract: Zusammenfassung Schon seit Beginn des zwanzigsten Jahrhunderts ist bekannt, dass Tumoren
im Vergleich zu gesundem Gewebe einen veränderten Stoffwechsel haben. Allerdings ist erst während
den letzten Jahrzenten bekannt geworden, dass Krebszellen ihren Stoffwechsel als Folge von Anhäufung
genetischer Mutationen umprogrammieren können. Entstehung von Darmkrebs ist ein klassisches Beispiel
für die Tumorigenese und beschreibt die Entwicklung normaler Schleimhaut über verschiedene Stadien
gutartiger Tumoren (Adenomen) hin zu bösartigem Darmkarzinom. Viele der genetischen Veränderungen,
die zur Entwicklung dieser einzelnen Stadien führen sind bekannt und für einige der am häufigsten mu-
tierten Gene in Darmkrebs, MYC, TP53 or KRAS, konnte eine Verbindung zu einer Stoffwechseländerung
in Krebs nachgewiesen werden. Allerdings ist unklar, wie diese genetischen Faktoren zur Veränderung des
Stoffwechsels während der Darmkrebs- entstehung beitragen. Ziel dieser Dissertation ist es, die metabolis-
chen Veränderungen in gutartigen Darmtumoren und Darmkrebs anhand von Metabolomics- und Tran-
scriptomics Analysen explorativ zu untersuchen. Da die Grösse der verwendeten Darmbiopsien sehr klein
ist, beschreiben die ersten Kapitel die Entwicklung neuartiger Methoden zur umfassenden Analyse des
Metaboloms und Lipidoms aus kleinen Probenmengen. Es wurden zwei sich ergänzende Methoden en-
twickelt, die auf Kapillarfluss- Flüssigchromatographie, gekoppelt mit Massenspektrometrie (capLCMS)
basieren. Beide Methoden konnten eine sensitive Quantifizierung der meisten getesteten Reinsubstanzen
im femtomolaren Bereich ermöglichen. Angewendet auf Metabolitenextrakte von Darmgewebe konnten
wir zeigen, dass 50% der detektierten Massen in der KEGG Metabolitendatenbank auffindbar waren,
ausserdem 700 verschiedene Lipide. Relative Standard- abweichungen der quantifizierten Metaboliten la-
gen im Bereich zwischen 15 und 20%, was einer reproduzierbaren Methode entspricht und es ermöglicht,
die Metabolomunterschiede zwischen Darmkrebs und Normalgewebe zu untersuchen. Desweiteren wird
die Entwicklung einer neuen Technik zur Auswertung von LCMS Rohdaten beschrieben. Diese Tech-
nik hat das Ziel, Metaboliten mit geringem Vorkommen besser zu detektieren. Anstelle jede einzelne
Rohdatei einer LCMS-Analyse individuell zu bearbeiten, ist die Idee dieser Methode, alle gewonnenen
LCMS-Daten zusammenzuführen und Metaboliten auf dem so entstandenen kombinierten Datensatz zu
identifizieren. Die entwickelte Methode wurde mit einer bestehenden Software, XCMS, verglichen. In
diesem Vergleich zeigte sich, dass unsere Methode bis zu zehnmal mehr Metaboliten detektieren kann als
XCMS. Darüber hinaus waren die Intensitäten der Metabolitensignale, die nur durch unsere Methode
identifizierbar waren, zehnmal geringer. Diese Beobachtungen zeigen, dass der Ansatz, LCMS Daten
zusammenzuführen tatsächlich dazu führen kann, Metaboliten mit geringer Menge besser zu detektieren.
Anschliessend wurden die entwickelten Metabolomics und Lipidomics Methoden, zusammen mit bere-
its vorhandenen Transcriptomics Daten dazu verwendet, die Stoffwechseländerungen in Darmkrebs und
Darmkrebsvorstufen zu untersuchen. Interessanterweise stellte sich heraus, dass die meisten Änderungen
in der Expression von Enzymgenen und die Änderung der Metabolitenkonzentration zwischen Adenom
und Darmkrebs sehr ähnlich waren, was erklären würde dass die Änderung im Stoffwechsel schon in
frühen Darmkrebsstadien stattfindet. Zu den beobachteten Stoffwechselwegen zählen Glykolyse, Prolin-
Serin und Nukleotid- biosynthese, sowie Glutaminstoffwechsel. Die meisten Enzymgene, die in diesen
Stoffwechselwegen involviert waren, korrelierten mit der Expression des MYC Gens, ausserdem mit Ziel-
genen von c-Myc selbst, was darauf hinweist dass diese Gene durch den wnt-Signalweg kontrolliert sind.
Andere beobachtete Änderungen in der Genexpression oder in den Metabolitenkonzentrationen waren
nur in Darmkrebs zu beobachten, aber nicht in den Adenomen. Hierzu zählt die Hochregulierung der
solute carrier Gene SLC7A5, SLC2A3 or SLC2A1, welche für die Aufnahme von Glukose und neutraler
Aminosäuren verantwortlich sind. Ausserdem wurde eine Hochregulierung von Genen für die Synthese
sehr langer, mehrfach ungesättigter Fettsäuren (VLC-PUFA) gezeigt. Diese Beobachtung wurde dadurch
untermauert, dass die Anzahl der meisten Lipidklassen mit konjugierten VLC-PUFA in Darmkrebs zu-
nahm, während Lipide mit kurzen und gesättigten Fettsäuren abnahm. Zusammen verweisen diese Ergeb-
nisse auf eine verstärkte Biosynthese mehrfach ungesättigter Fettsäuren in Darmkrebszellen.
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Zusammenfassung 
Schon seit Beginn des zwanzigsten Jahrhunderts ist bekannt, dass Tumoren 
im Vergleich zu gesundem Gewebe einen veränderten Stoffwechsel haben. 
Allerdings ist erst während den letzten Jahrzenten bekannt geworden, dass 
Krebszellen ihren Stoffwechsel als Folge von Anhäufung genetischer 
Mutationen umprogrammieren können. Entstehung von Darmkrebs ist ein 
klassisches Beispiel für die Tumorigenese und beschreibt die Entwicklung 
normaler Schleimhaut über verschiedene Stadien gutartiger Tumoren 
(Adenomen) hin zu bösartigem Darmkarzinom. Viele der genetischen 
Veränderungen, die zur Entwicklung dieser einzelnen Stadien führen sind 
bekannt und für einige der am häufigsten mutierten Gene in Darmkrebs, 
MYC, TP53 or KRAS, konnte eine Verbindung zu einer Stoffwechseländerung 
in Krebs nachgewiesen werden. Allerdings ist unklar, wie diese genetischen 
Faktoren zur Veränderung des Stoffwechsels während der Darmkrebs-
entstehung beitragen. Ziel dieser Dissertation ist es, die metabolischen 
Veränderungen in gutartigen Darmtumoren und Darmkrebs anhand von 
Metabolomics- und Transcriptomics Analysen explorativ zu untersuchen. Da 
die Grösse der verwendeten Darmbiopsien sehr klein ist, beschreiben die 
ersten Kapitel die Entwicklung neuartiger Methoden zur umfassenden 
Analyse des Metaboloms und Lipidoms aus kleinen Probenmengen. Es 
wurden zwei sich ergänzende Methoden entwickelt, die auf Kapillarfluss-
Flüssigchromatographie, gekoppelt mit Massenspektrometrie (capLCMS) 
basieren. Beide Methoden konnten eine sensitive Quantifizierung der meisten 
getesteten Reinsubstanzen im femtomolaren Bereich ermöglichen. 
Angewendet auf Metabolitenextrakte von Darmgewebe konnten wir zeigen, 
dass 50% der detektierten Massen in der KEGG Metabolitendatenbank 
auffindbar waren, ausserdem 700 verschiedene Lipide. Relative Standard-
abweichungen der quantifizierten Metaboliten lagen im Bereich zwischen 15 
und 20%, was einer reproduzierbaren Methode entspricht und es ermöglicht, 
die Metabolomunterschiede zwischen Darmkrebs und Normalgewebe zu 
untersuchen. Desweiteren wird die Entwicklung einer neuen Technik zur 
Auswertung von LCMS Rohdaten beschrieben. Diese Technik hat das Ziel, 
Metaboliten mit geringem Vorkommen besser zu detektieren. Anstelle jede 
einzelne Rohdatei einer LCMS-Analyse individuell zu bearbeiten, ist die Idee 
 5 
dieser Methode, alle gewonnenen LCMS-Daten zusammenzuführen und 
Metaboliten auf dem so entstandenen kombinierten Datensatz zu 
identifizieren. Die entwickelte Methode wurde mit einer bestehenden 
Software, XCMS, verglichen. In diesem Vergleich zeigte sich, dass unsere 
Methode bis zu zehnmal mehr Metaboliten detektieren kann als XCMS. 
Darüber hinaus waren die Intensitäten der Metabolitensignale, die nur durch 
unsere Methode identifizierbar waren, zehnmal geringer. Diese 
Beobachtungen zeigen, dass der Ansatz, LCMS Daten zusammenzuführen 
tatsächlich dazu führen kann, Metaboliten mit geringer Menge besser zu 
detektieren. Anschliessend wurden die entwickelten Metabolomics und 
Lipidomics Methoden, zusammen mit bereits vorhandenen Transcriptomics 
Daten dazu verwendet, die Stoffwechseländerungen in Darmkrebs und 
Darmkrebsvorstufen zu untersuchen. Interessanterweise stellte sich heraus, 
dass die meisten Änderungen in der Expression von Enzymgenen und die 
Änderung der Metabolitenkonzentration zwischen Adenom und Darmkrebs 
sehr ähnlich waren, was erklären würde dass die Änderung im Stoffwechsel  
schon in frühen Darmkrebsstadien stattfindet. Zu den beobachteten 
Stoffwechselwegen zählen Glykolyse, Prolin- Serin und Nukleotid-
biosynthese, sowie Glutaminstoffwechsel. Die meisten Enzymgene, die in 
diesen Stoffwechselwegen involviert waren, korrelierten mit der Expression 
des MYC Gens, ausserdem mit Zielgenen von c-Myc selbst, was darauf 
hinweist dass diese Gene durch den wnt-Signalweg kontrolliert sind. Andere 
beobachtete Änderungen in der Genexpression oder in den 
Metabolitenkonzentrationen waren nur in Darmkrebs zu beobachten, aber 
nicht in den Adenomen. Hierzu zählt die Hochregulierung der solute carrier 
Gene SLC7A5, SLC2A3 or SLC2A1, welche für die Aufnahme von Glukose 
und neutraler Aminosäuren verantwortlich sind. Ausserdem wurde eine 
Hochregulierung von Genen für die Synthese sehr langer, mehrfach 
ungesättigter Fettsäuren (VLC-PUFA) gezeigt. Diese Beobachtung wurde 
dadurch untermauert, dass die Anzahl der meisten Lipidklassen mit 
konjugierten VLC-PUFA in Darmkrebs zunahm, während Lipide mit kurzen 
und gesättigten Fettsäuren abnahm. Zusammen verweisen diese Ergebnisse 
auf eine verstärkte Biosynthese mehrfach ungesättigter Fettsäuren in 
Darmkrebszellen.   
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Summary 
It was already shown at the beginning of the twentieth century that tumors 
have a different metabolic phenotype compared to normal cells. However 
only during the last decade it became evident that cancer cells undergo a 
metabolic reprogramming because of accumulations of genetic mutations and 
subsequent alterations in molecular signalling pathways which ultimately 
lead to abnormal cell proliferation. Development of colorectal cancer is a 
classical example for tumorigenesis and describes the transition of normal 
mucosa to a malignant colorectal carcinoma via different stages of 
premalignant lesions (adenomas). Many of the genetic alterations which lead 
to each transition step are known and some of the most commonly altered 
genes in colorectal cancer, MYC, TP53 or KRAS, have been linked to the 
reprogramming of cancer metabolism. However, it is unclear how these 
factors contribute to metabolic alterations during colorectal cancer 
development.  
This thesis aims for an exploratory analysis of metabolic changes in human 
colorectal adenomas and cancers by applying untargeted metabolomics and 
transcriptomics techniques. Because of limited biological sample sizes, the 
first two chapters of the thesis describe the development of novel technologies 
for a comprehensive analysis of the metabolome and lipidome from a small 
amount of colorectal biopsies. Two complementary capillary liquid 
chromatography mass spectrometry (capLCMS) methods were developed, 
both providing a sensitive quantification of most tested standard metabolites 
in the femtomolar range. Both methods cover about 50% of the masses 
annotated in the KEGG metabolite database and about 700 lipids. Relative 
standard deviations lie in the range between 15 and 20%, which makes the 
methods reproducible and applicable for the comparison between tumors and 
normal mucosa samples. 
 We then describe the development of a novel LCMS raw data processing 
technique, which aims to an improved quantification of low abundant 
metabolites. The basic idea of the proposed algorithm is to merge multiple 
LCMS runs together and to detect metabolites on this merged dataset instead 
of in each single file. We compared our algorithm with existing software. We 
 7 
demonstrate that our approach yields up to ten times more metabolite 
features than the open source software tool XCMS. Moreover, metabolites 
detected uniquely by the new method, were ten times lower in intensity as 
the lowest abundance metabolites detected by XCMS. This indicates that the 
new algorithm is indeed more sensitive towards low abundant metabolites.  
Finally, we applied our lipidomics and metabolomics techniques to 
investigate the metabolic alteration of colorectal tumors, in combination with 
previously acquired transcriptomics data. Most interestingly, many 
alterations in gene expression of enzymes and in metabolite abundance were 
similar in adenomas and cancers, indicating that reprogramming of 
metabolism occurs early in colorectal tumorigenesis. These alterations 
included metabolic pathways involved in glycolysis, nucleotide biosynthesis, 
and glutamine, proline and serine metabolism. Most of the enzyme genes 
expressed in these pathways correlated with the expression of MYC and its 
target genes, which indicates that theses enzymes are controlled by the Wnt 
pathway. Other alterations in gene expression or metabolite abundance were 
observable in cancer but not in adenomas, such as the upregulation of solute 
carrier genes SLC7A5, SLC2A3 or SLC2A1 whose products are involved in the 
uptake of glucose and neutral amino acids. Also, the expression of genes 
encoding proteins that are involved in the synthesis of very long, 
polyunsaturated fatty acids (VLC-PUFA) were more increased in cancer than 
in adenomas. Complementing this observation, most of the lipids containing 
VLC-PUFA were increased in cancers, while lipids with short and saturated 
fatty acyls were decreased, indicating that cancer cells have an increased 
biosynthetic activity for VLC-PUFA. 
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Introduction 
Colorectal Cancer 
Colon and rectal cancer (colorectal cancer, CRC) is worldwide the third most 
commonly diagnosed cancer (Jemal et al., 2011) and CRC related death rates 
tend to decline in developed countries, where incidence is more common 
(Siegel et al., 2013). These declines in mortalities reflect an improvement in 
early diagnostics and treatment of this disease during the last 40 years (Cress 
et al., 2006). However, CRC still remains the third most frequent cancer 
fatality in the USA (Siegel et al., 2013). 
CRC is believed to arise from premalignant neoplastic lesions (adenomas) and 
the progress which leads to transformation of normal mucosa to malignant 
tumors was extensively studied in the past (Fearon and Vogelstein, 1990). 
Hundreds of somatic mutations are acquired during tumor development, 
among which only a small subset of “driver mutations” are suspected to be 
responsible for the progression of cancer (Stratton et al., 2009). There are three 
main driver gene mutations involved in a prominent fraction of CRC: APC, 
KRAS and TP53 (Fearon, 2011). These main driver genes in CRC are already 
known for several years and even after most recent genome screenings there 
are no other mutation frequencies as high as in KRAS (45.1%), TP53 (58.6%) 
and APC (81.9%) (Kandoth et al., 2013). CRC is typically divided into two 
subclasses: About 85% of CRC cases are considered as chromosomally 
unstable as they contain frequent allelic losses. APC, KRAS and TP53 somatic 
mutations are typically found in patients having these tumor forms. The other 
15% of the cases typically show 10-fold more overall mutations including 
microsatellite instability (MSI) due to a defect of the DNA mismatch repair. 
These hypermutated tumors often contain mutations or epigenetic silencing 
in the mismatch repair genes MLH1, PMS2, MSH2, and MSH6 (Marra and 
Schar, 1999; Truninger et al., 2005; Muzny et al., 2012). It is estimated that 20% 
CRC cases have a hereditary background, where familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) are 
the major mendelian forms (Lynch and la Chapelle, 2003). The most common 
form HNPCC, also termed Lynch syndrome, is typically characterized by MSI 
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positive tumors and by germline mutations of one of the mismatch repair 
genes. FAP is an autosomal dominantly inherited disease mostly caused by 
germline mutations in APC (>90%) and patients develop hundreds of 
adenomas early in their life. In sporadic CRC, novel somatic mutations lead 
first to the development of adenomas and further independent mutations lead 
finally to cancer, a progress which is estimated to take around 20 years and 
CRC is therefore typically diagnosed only in elder people (Jones et al., 2008; 
Vogelstein et al., 2013). The genetic predisposition of FAP and HNPCC 
however accelerates CRC development either at the formation of adenomas 
(FAP) or at the transition from adenomas to carcinomas (HNPCC).  
The inactivation of APC or other Wnt-signalling genes is considered as the 
first key event in colorectal tumorigenesis (Clevers and Nusse, 2012). Stem 
cells within the intestinal crypts are normally responsible for the renewal of 
the mucosal epithelium. Activation of the Wnt-pathway drives the 
transformation of these cells and leads to the formation of neoplasia (Barker et 
al., 2008). The most common form of such colorectal neoplasia are 
adenomatous polypoid lesions (or polyps) and are characterized by 
protruding growth into the gut lumen, either sessile or with a stalk (Cattaneo 
et al., 2010). Other lesion forms do not protrude into the gut lumen and are 
either slightly elevated, or flat or depressed. Despite the huge progress in 
molecular biology and clinical management of colorectal cancers, the removal 
of precancerous lesions during colonoscopy is considered as the most efficient 
and reliable tool to reduce CRC incidence and mortality (Winawer et al., 1993; 
Lena, 2013). 
 
Cancer Metabolism 
Today it is widely acknowledged that cancer is a genetic disease and therefore 
most tumors are believed to develop from alterations in the genome of 
dedicated tumor cells, for example by activation or deactivation of signalling 
pathway genes (Vogelstein and Kinzler, 2004). From a historical perspective 
however, the first molecular alterations of cancer were discovered on the level 
of metabolism (Warburg, 1926). In the 1920s, Otto Warburg showed that 
tumors metabolize glucose via glycolysis instead of oxidative respiration 
(Koppenol et al., 2011). The resulting metabolic phenotype was the 
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production of lactic acid, even if enough oxygen was supplied. This 
phenomenon that cancer cells produce lactic acid from glucose is now widely 
appreciated as Warburg effect. For a long time, Warburg believed that the 
origin of cancer cells are explained by an impairment of respiration, a 
controversial hypothesis which was hotly debated until the 1970s (Warburg, 
1956; Weinhouse et al., 1956; Weinhouse, 1976). After Warburg’s death in 1970 
the field of cancer research was greatly influenced by the discovery of 
oncogenes and tumor suppressor genes (Weinberg, 1994). This basic concept 
of cancer cell proliferation by gene activation (oncogene) or by inhibiting 
activity of gene product (tumor suppressor gene) is until today a basic dogma 
of tumorigenesis (Vogelstein and Kinzler, 2004). During these years the 
interest in cancer metabolism decreased due to the popularity and the 
importance of molecular genetics in cancer (Figure i). However, during the 
last decade cancer metabolism experienced a renaissance within the cancer 
research community (Figure i), and changes in energy metabolism has been 
acknowledged as one of the prominent hallmarks of cancer (Hanahan and 
Weinberg, 2011). This recent gain of interest is explained by the discovery of 
tight associations between genetic alterations and metabolism in cancer cells. 
Among these genetic-metabolic associations we can distinguish between two 
kinds of observations: 1) Cancer-associated mutations of enzyme genes and 2) 
Transcriptional or post transcriptional regulation of enzymatic genes via 
oncoproteins and tumor suppressors. Interestingly, most of the so far 
discovered cases of direct mutations in enzyme genes represent 
mitochondrial genes involved in TCA cycle (Koppenol et al., 2011). Mutations 
in fumarate hydratase (FH), succinate dehydrogenase (SDH) and isocitrate 
dehydrogenase (IDH1) are an indication that Warburg’s hypothesis of 
defective mitochondria as cause of cancer may hold true for a few cancer 
types (Baysal et al., 2000; Tomlinson et al., 2002; Parsons et al., 2008). In many 
other cases however, metabolic reprogramming of cancer cells is mediated by 
oncogenes and tumor suppressor genes (Ward and Thompson, 2012). 
Glycolysis is one target of metabolic reprogramming, and many glycolytic 
genes are upregulated in cancer (Kroemer and Pouyssegur, 2008). 
Upregulated glycolytic activity, and especially the increase in lactate 
dehydrogenase confirm the Warburg effect. In addition to glycolysis, cancer 
cells rely on biosynthetic processes in order to provide building blocks for 
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DNA, lipid and protein biomass (DeBerardinis et al., 2008). Many major 
oncogenes and tumor suppressor genes such as p53, HIF1, AKT, RAS, VHL, c-
MYC are directly linked to reprogramming of metabolism in cancer 
(Koppenol et al., 2011). In addition to glucose, glutamine plays a major role as 
means of participating in bioenergetic and biosynthethic reactions in cancer 
(DeBerardinis and Cheng, 2009). Glutaminolysis and related metabolic 
processes such as nucleotide biosynthesis are mainly regulated by c-Myc 
(Wise et al., 2008). Some very recent findings report the rediscovery of 
metabolic pathways, such as those of glycine and proline to be involved in 
metabolic reprogramming of cancer cells (Liu et al., 2012; Locasale, 2013). 
 
Figure i: Interest in cancer metabolism research between 1920 and 2014 indicated by the three most 
highly cited publications of Otto Warburg in this topic. Citation peaks are between 1920 and 1930, 
between 1955 and 1965 and from 2005 until today. Origin of cancer cells (Warburg, 1956), Respiratory 
impairment in cancer cells (Weinhouse et al., 1956), on the metabolism of carcinoma cells (Warburg, 
1925). Data was retrieved from https://www.webofknowledge.com. 
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Investigation of metabolism using mass spectrometry based 
metabolomics 
Metabolites are small molecules with a molecular weight typically below 2000 
Da. As a product of enzymatic activity they are the ultimate products of a 
biological system (Fiehn, 2002). Metabolites are chemically very heterogenous 
and include different classes such as amino acids, lipids, nucleotides or 
central carbon metabolites (Milne et al., 2013). In addition to these very 
common classes, there exists a vast amount of secondary metabolites, for 
example the many diverse natural products of plants (Roepenack-Lahaye et 
al., 2004). Environmental factors such as chemicals, drugs or microbes 
additionally contribute to the overall composition of metabolites within an 
organism. The total sum of all these endogenous and exogenous compounds 
is called the metabolome. It it estimated that the human metabolome consists 
of about 100000 small molecules and the current version of the human 
metabolome database (HMDB) lists alone 29332 endogenous metabolites 
(Milne et al., 2013; Wishart et al., 2013). Technical advances in the fields of 
mass spectrometry (MS) allow us nowadays to detect and quantify thousands 
of metabolites, enabling us to analyse a broad range of the metabolome (Patti 
et al., 2012). In addition to genomics, transcriptomics and proteomics, 
metabolomics provides us therefore an important tool for systems biology 
and functional genomics (Hollywood et al., 2006).  
 In contrast to genomics and transcriptomics, MS based metabolomics is not 
capable to cover most of its individual parts, i.e. each metabolite, with a single 
technological setup. While novel mass spectrometers with high acquisition 
rates already allow for comprehensive analysis of the proteome (Hebert et al., 
2014), the heterogenous nature of metabolites hamper the development of an 
all-encompassing method. Metabolomics is therefore typically divided into a 
1) Targeted or 2) Untargeted analysis of metabolites (Patti et al., 2012). 
Targeted metabolomics generally aims for the quantification of a small subset 
of metabolites, often employing a triple quadrupole mass spectrometer (Lu et 
al., 2008). These instruments are then used in multiple reaction monitoring 
mode (MRM), where MS parameters have to be individually optimized for 
the metabolites of interest before the real metabolomics experiment can be 
performed: For each metabolite, a pure standard compound needs to be 
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obtained in order to optimize the following parameters: 1) A precursor ion for 
the isolation of the most abundant mass of each metabolite, 2) the most 
abundant fragment ion which is optimally highly specific for each metabolite 
and 3) the optimal collision energy which is needed to gain optimal yield of 
the fragment ion (Kitteringham et al., 2009). The advantages of this technique 
are a high sensitivity, good reproducibility and a broad dynamic range. Very 
often this method is also highly specific for each metabolite, leading to an 
unambiguous detection. Typically, the focus of a targeted metabolomics 
method is to specifically quantify a subset class of metabolites, such as central 
carbon metabolites (Luo et al., 2007).  
Untargeted metabolomics, or metabolic profiling, has the general aim to 
quantify as much metabolites as possible in a biological sample (Patti et al., 
2012). NMR and mass spectrometry are the most frequent analytical 
techniques for this approach (Dunn et al., 2005). However with modern mass 
spectrometers, thousands of mass peaks can be monitored with a high mass 
accuracy and a good sensitivity, making MS and especially liquid 
chromatography mass spectrometry (LCMS) the method of choice for 
untargeted metabolomics (Forcisi et al., 2013). The big advantage of LCMS 
based untargeted metabolomics is therefore the possibility to screen a large 
amount of metabolites, however the major bottleneck of this technique is data 
interpretation (Patti et al., 2013). Typically, high mass accuracy full scan 
LCMS data are highly complex and file sizes can approach gigabyte 
dimensions. In order to interpret such data, a first step is to generate data 
tables from the raw data, where each identified signal is annotated by its 
information on the mass to charge (m/z), retention time (RT) and intensity 
dimension (Sugimoto et al., 2012). As a next step, accurate masses from the 
data table are searched in metabolite databases such as the human 
metabolome database (Wishart et al., 2007), METLIN (Tautenhahn et al., 2012) 
or KEGG (Ogata et al., 1999), in order to putatively annotate possible 
metabolite hits. 
Untargeted metabolomics made huge progress during the last decade and the 
modern techniques allow for a comprehensive analysis of the metabolome. 
The nowadays challenges in untargeted metabolomics are to improve the 
dynamic range and sensitivity of the analytical methods in order to cover a 
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broad range of metabolite classes from a low amount of biological material 
(Koek et al., 2010; Ivanisevic et al., 2013). One big success for the nowadays 
comprehensive and sensitive proteomics techniques was the development of 
LCMS techniques based on nanoflow and nanoelectrospray (Shen et al., 2002). 
Very low flow rates allow for a high chromatographic separation and very 
good sensitivity. Despite these advantages, nanoLCMS applications are very 
uncommon in metabolomics research. A few metabolomics applications using 
nanoLCMS demonstrate a sensitivity range which is comparable to targeted 
approaches or even better (Myint et al., 2009a; 2009b; Kiefer et al., 2010). 
However, normal flow LCMS is still the dominating analytical method in 
both untargeted and targeted metabolomics. 
 
Aim of this thesis 
As mentioned above, the tumor suppressor genes APC and TP53, as well as 
the oncogone KRAS play an important role for the transition from normal 
mucosa to adenoma and cancer (Fearon and Vogelstein, 1990). As oncogenes 
and tumor suppressors were reported to be involved in the reprogramming of 
metabolism in cancer cells, we hypothesized that metabolic alterations might 
be different in each stage of tumorigenesis. TP53 was shown to be involved in 
glycolysis and pentose phosphate metabolism and more recently also in 
glutamine metabolism (Bensaad et al., 2006; Hu et al., 2010; Suzuki et al., 
2010). Also more recently it was shown that KRAS stimulates glucose uptake 
and pentose phosphate biosynthesis (Ying et al., 2012). Most interestingly, as 
a consequence of wnt pathway deregulation in the development of 
premalignant colorectal tumors, the transcription factor c-Myc is 
overexpressed in basically all early colorectal lesions (Sansom et al., 2007; 
Wilkins and Sansom, 2008). Given the fact that c-Myc plays a role in many 
different metabolic processes (Li and Simon, 2013), we hypothesized that 
reprogramming of metabolism is already an early event in tumorigenesis. 
During the last years, a large amount of gene expression data from colorectal 
tumor biopsies, including adenomas and cancer were acquired (Cattaneo et 
al., 2010; Maglietta et al., 2012). Guided by these valuable data and motivated 
by the recent advances in cancer metabolism, the presented work aims for an 
exploratory analysis of the metabolic changes during colorectal cancer 
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development by a combined analysis of the metabolome and transcriptome of 
human colorectal tumors. 
A major technical problem for the analysis of colorectal biopsies is that only a 
limited amount of sample is available, especially for adenomatous lesions 
(Sabates Bellver et al., 2007). The premise for the analysis of a colorectal tissue 
metabolome was therefore to establish analytical methods for the analysis of 
less than 5 mg biopsies. This thesis is divided into three parts: The 
development of two different technical strategies for the improvement of 
sensitivity in mass spectrometry based metabolomics and the investigation of 
metabolic changes of colorectal cancer development:  
 
Chapter 1: 
Decreased column diameter in LCMS analytics was described to improve the 
ionization, ion suppression effects and overall sensitivity compared to normal 
flow LCMS (Shen et al., 2002). In this chapter the development of two 
complementary methods based on capillary LCMS for a comprehensive 
analysis of the lipidome and metabolome are presented and discussed. 
 
Chapter 2: 
Reliable and sensitive computational methods are essential for the analysis of 
untargeted metabolomics LCMS data. In this chapter we will discuss the 
development of a novel algorithm with an increased sensitivity towards low 
abundant metabolites. 
 
Chapter 3: 
In this chapter we will combine transcriptomics and metabolomics data of 
colorectal biopsies in order to investigate the metabolic changes during 
colorectal cancer development. 
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1.1 Abstract 
Metabolomics is considered as a complementary method to proteomics and 
transcriptomics. The comprehensive, efficient identification and 
quantification of the metabolites and lipids in any given biological sample is 
still a major challenge within the field, especially when samples of limited 
volume are to be analyzed. Here we present a complementary set of 
untargeted metabolomics methods which are based on capillary scale ultra-
performance liquid chromatography mass spectrometry (capLCMS) for the 
comprehensive analysis of metabolites ranging from very polar (sugars) to 
very non-polar (lipids) compounds. Two chromatographic setups were 
chosen, one based on hydrophilic interaction chromatography (HILIC) and 
the other on reversed phase chromatography (RP). Limits of detection for 
both methods were shown to be in the low picomolar to femtomolar range for 
most of a selection of 190 reference compounds, covering all major metabolite 
classes. We demonstrate a broad metabolome and lipidome coverage by 
applying both methods to colorectal tissue extracts from biopsies with less 
than 5 mg fresh weight. About 50% of the KEGG metabolome database and 
688 lipids could be annotated by accurate mass and with good relative 
standard deviation (RSD) values between 15 and 20%. A total run time of only 
35 minutes for both methods allows for a high throughput analysis.  
1.2 Introduction 
Metabolomics aims for a comprehensive quantification of small molecules in 
a biological system (Baker, 2011). With technological advances during the last 
years, liquid chromatography coupled to mass spectrometry (LCMS) became 
a powerful tool to measure a broad range of metabolites (Patti et al., 2012). In 
contrast to the analysis of typically hydrophobic peptides in shotgun-
proteomics, small molecules are chemically very heterogeneous and can 
range from very polar (e.g. sugars) to very non-polar (lipids) compounds. 
Therefore, quantification of the complete metabolome is impossible to achieve 
in a single analytical setup. RP chromatography is a very popular and 
powerful analytical method but is typically restricted to the analysis of lipids 
and other hydrophobic molecules (Lu et al., 2008). For the analysis of polar 
metabolomes, hydrophilic stationary phases (Bajad et al., 2006; Pesek et al., 
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2008) or reversed phase chromatography which include ion pairing reagents 
as a polar anchor (Coulier et al., 2006) were described. 
A further analytical challenge is sensitivity. For many biological applications, 
metabolite extracts originate from a small amount of cells or small tissues, 
and therefore it is desirable that LCMS systems are able to analyse low 
amounts of metabolites. One strategy to gain sensitivity is the reduction of the 
chromatographic column dimensions, i.e. column diameter and flow rate 
(Abian et al., 1999). Since its first successful application in the separation of 
tryptic protein digests, nanoLCMS is nowadays very popular in the field of 
proteomics (Shen et al., 2002). Metabolomics and lipidomics on the other hand 
mainly rely on normal flow LCMS. Only a few studies demonstrated the use 
of nanoflow for metabolomics applications. Polar metabolomes were shown 
to be retained using self packed capillary columns filled with stationary 
material targeting either cationic or anionic metabolomes (Myint et al., 2009a; 
2009b). Another protocol employs ion pairing chromatography with 
commercially available nanoLC columns (Kiefer et al., 2010). For unpolar 
metabolomes or lipidomes, a reversed phase capillary LCMS with self packed 
columns was described (Gao et al., 2012). All of these protocols share a very 
high sensitivity with limits of detection values in the low femtomolar range or 
below. Since each of these methods target only a certain class of metabolites, a 
combination of different LCMS methods would be necessary in order to cover 
the metabolome as comprehensive as possible. Combining different methods 
however increases total instrument time of each sample. All of the described 
methods employ gradients with a total run time of at least 60 minutes. With 
the advent of particle sized below 2 µm and ultrahigh pressure 
chromatography (UPLC), fast chromatographic runs without losses in 
resolution are possible (Plumb et al., 2004). In this study we present two fast 
and sensitive, capLCMS methods based on UPLC chromatography to cover a 
large range of chemically different metabolite classes. Fast gradients 
employing reversed phase (RP) for lipidome and hydrophilic interaction 
chromatography (HILIC) for metabolome analysis are used and we 
demonstrate a comprehensive analysis of both non polar and polar 
compounds within 35 minutes of total run time. 
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1.3 Material and Methods 
1.3.1 Manufacturing of capillary columns 
Polyimide coated fused silica tubing with an internal diameter of 200 µm and 
an outer diameter of 360 µm were used for capillary LCMS analysis. The silica 
tubings were obtained from BGB Analytik AG, Switzerland. The capillaries 
were tapered using a laser capillary puller and chromatography material was 
filled under nitrogen gas pressure at 30 bar (Myint et al., 2009a).  
1.3.2 Selection of HPLC/UPLC materials for the evaluation of polar 
metabolites 
Four different HPLC materials and mobile phases for the analysis of polar 
metabolites were selected in order to test their applicability in capillary-scale 
LCMS analysis: 1) Imtakt Scherzo SM-C18 mixed mode column material, 3 
µm, 25 mm with 1.5 mM Acetic acid, 5% Methanol as mobile phase A and 
50% isopropanol, 100 mM ammonium acetate as mobile phase B. A 10 minute 
gradient from 0-100% B was employed. 2) Waters BEH amide, 1.7 um, 25 mm 
with mobile phase A: 50% acetonitrile, 10 mM ammonium acetate and B: 95% 
acetonitrile, 10 mM ammonium acetate. For both mobile phase buffers, 25% 
ammonium solution was used to adjust for pH 9. A 20 min gradient from 
98%B to 98% A was used. 3) Microsolv Diamond Hydride, 4um, 30 mm was 
employed using a gradient of 0% to 60% A within 20 minutes, with A=H2O 
and B=90% acetonitrile. 10 mM ammonium acetate and 10 mM acetic acid 
was added to both mobile phases. 4) Waters HSS T3 C18 column, 1.8 um, 15 
mm was used for ion pairing chromatography. Solvent A was 1 mM 
tributylamine, 1.5 mM acetic acid, 5% MeOH, pH 4. Solvent B was methanol. 
A solvent gradient from 100%A to 0%A within 20 minutes was employed.  
For the analysis of hydrophobic molecules and lipids, we used a Waters HSS 
T3 C18 column (1.8 um, 5 mm), using H2O as mobile phase A and 90% 
isopropanol/10% acetonitrile as mobile phase B. 5 mM ammonium acetate 
was added to both mobile phases. A 10 min elution gradient from 100% to 0% 
A was used. 
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1.3.3 LCMS analysis 
Analyses were performed using a nanoACQUITY system coupled to a Synapt 
G2HD mass spectrometer (Waters Corp., Milford, USA). For mass 
spectrometry, all analyses for polar metabolites were done in negative mode 
using 1.2 kV capillary voltage, 30 V sampling cone voltage and 3 V extraction 
cone voltage. Source temperature was set to 100 °C and sheet gas was applied. 
For lipids and hydrophobic metabolites we used positive mode acquisition, 
using the same settings as in negative mode with the exception of 3.0 kV 
capillary voltage. MS Data was acquired in MSE mode. Trap Collision Energy 
was set to 20-40 V ramp. Mass analysis was set to resolution mode (FWHM 
~20000) and a m/z window between 50-1200 was selected. Before injection, 
samples were diluted 1:5 using the respective initial solvent composition. 
1.3.4 Metabolite standards 
For the characterization of the different HPLC column materials we evaluated 
the performance of a standard metabolite mixture, consisting of 89 
compounds at a concentration of 100 uM each (Table A-2). For the evaluation 
of the finally proposed method, we selected 200 small molecule standards, 
covering different metabolite classes from very polar to non-polar 
compounds. For LCMS analysis of all standards, we designed 20 mixtures 
containing 10 metabolites each. A dilution set of the 20 mixtures was created 
with a concentration range between 100 uM and 100 fM. A list of all standards 
and their arrangement within the 20 mixes can be seen in (Table 1.3). All 
standard substances were obtained from Sigma Aldrich in the highest 
availiable purity. 
1.3.5 Metabolite extracts from colorectal tissue 
In order to investigate technical and biological variations in real samples, we 
collected biopsies from colorectal tissue. Five specimens of normal mucosa 
and cancer were collected from two patients, respectively. Another five 
specimens of normal mucosa were collected from two additional patients. To 
evaluated the reproducibility of the method, we pooled aliquots of all 
samples together. This pooled sample was analysed ten times. Additionally, 
each individual sample was analysed in three technical replicates. Ultrapure 
methanol was added to a mixture of internal standards (Appendix Table A-1). 
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For the extraction of metabolites, 100 ul of internal standard containing 
methanol was added to 5 mg of each biopsy and the tissue was homogenized 
by means of a glass homogenizer. The supernatant was collected and 
subsequently dried in a speedvac vacuum concentrator. The dry metabolite 
pellet was resuspended in ultrapure water, diluted 1:5 with injection solvent 
(50 mM NH4 Acetate in 90% ACN, 9% MeOH and 1% H2O, pH9) and 
transferred to autosampler vials for LCMS analysis. 
1.3.6 Data analysis 
Each Waters raw file was centroided and converted to vendor independent 
netCDF data format using MassLynx 4.1 and DataBridge Software from 
Waters. The netCDF data were processed using the open-source data 
processing software xcms (Smith et al., 2006). The analytical standards were 
processed using the matched filter algorithm, with the parameter settings 
snthresh=3 and step=0.01. From the genereted peak list we retrieved the 
parameters “into” (Peak Area), “sn” (signal-to-noise ration), “mz” (estimated 
accurate mass) and “rt” (estimated retention time average). For the processing 
of the colorectal tissue dataset we used xcms with the centWave algorithm 
(Tautenhahn et al., 2008) and the following parameter settings to generate 
peak tables: centWave: ppm=30 and snthresh=3, retcor=„obiwarp“, 
profStep=0.5 and group=„nearest“, mzCheck=0.01, rtCheck=15. For the 
calculation of relative standard deviations (RSD), no further data 
transformation was performed. For a between group analysis (bga) of the 
data, the peak tables were log(2)-transformed in advance. The bga function 
was called from the made4 package using the option „pca“ (Culhane et al., 
2005).  
1.4 Results and Discussion 
1.4.1 Selection of chromatographic material for very polar metabolites 
Our aim was to develop a metabolomics method which is sensitive enough to 
cover a wide range of substance classes from a small amount of sample. To 
achieve this goal of high sensitivity, our strategy was to employ capillary-
scale liquid-chromatography mass spectrometry (capLCMS) instead of 
normal-flow LCMS. It was shown that the decrease of inner column diameter 
from 1 mm to 250 um can lead to a significant increase of mass signal 
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intensity (Abian et al., 1999; Richard T Gallagher et al., 2003). Because of the 
chemically heterogeneous nature of the metabolome we decided to focus on 
the development of two different analytical methods: One method for very 
non-polar metabolites and lipids, and one method for very polar compounds. 
Reversed phase chromatography is commonly found in metabolomics 
applications and is popular due to very good separation performance but is 
restricted to hydrophobic metabolites or lipids (Yanes et al., 2011). To retain 
polar metabolomes by LCMS, different strategies were described in the 
literature. In order to find the most promising analytical technique for our 
capillary LCMS system, we evaluated four different chromatographic 
materials which were described for the analysis of polar metabolomes using 
normal flow LCMS: 1) HILIC chromatography employing a basic elution 
buffer system (modified from Bajad et al., 2006). Instead of the originally 
described material (Luna NH2 from Phenomenex, 5um particle size) we chose 
a similiar material with 1.7um particles, Waters BEH Amide. 2) A multimodal 
column material, Scherzo SM-C18 (3 um). This material combines cation and 
anion exchange with reverse-phase chromatography (modified from Yanes et 
al., 2011). 3) Reversed phase ion pairing chromatography (modified from 
Buescher et al., 2010). For this chromatography type, ion pairing reagents are 
added as a linker between polar analytes and non-polar stationary phase. For 
this method, we used Waters HSS T3 material (1.8 um) with tributylamine 
(TBA). 4) Aqueous normal phase chromatography (modified from Pesek et 
al., 2008). This type of chromatography employs hydride modified silica 
particles. A diamond hydride column (4 um) from Cogent was used. Each 
column material was filled into a home made tapered fused silica capillary 
tip. 
To evaluate the analytical performance between these four different LCMS 
systems, we analyzed a mixture of 89 polar metabolite standards (See 
Appendix Table A-2) at a concentration of 100 uM each (Figure 1.1). For each 
detected metabolite, the following properties were calculated: Peak area, 
retention factor k and signal-to-noise ratio (S/N). The retention factor k 
characterizes the migration of analyte in relation to the solvent front. k was 
calculated based on the formula 𝑘 = !!!!!!! , where tR is the retention time of the 
analyte and t0 is the elution time of the solvent front (Snyder et al., 2011). We 
estimated the solvent front based on the peak list produced by XCMS, where 
 26 
t0 was defined as the retention time of the earliest cohort of detected peaks. 
The most metabolites (70 of 89) were detected using Waters BEH Amide 
material, followed by Waters HSS T3+TBA (67), Imtakt Scherzo SM-C18 (64) 
and Cogent Diamond Hydride (58). In terms of signal sensitivity, BEH Amide 
showed a similiar overall signal intensity compared to the HSS T3+TBA and 
together they outperform Diamond Hydride and Scherzo SM-C18 (Figure 
1.1a). However, the signal-to-noise ratio of BEH Amide chromatogtaphy is 
better for most compounds compared to the other materials, indicating a 
better overall sensitivity of the BEH Amide chromatography (Figure 1.1 c). 
The best overall chromatographic behaviour was seen for BEH Amide or the 
Diamond Hydride material, indicated by a factor k higher than 1 for the most 
analytes (Figure 1.1 b). About a half of the compounds analyzed with Scherzo 
SM-C18 or HSS T3+TBA chromatography have k values around 0, indicating 
that these metabolites elute in the void volume. 
 
Figure 1.1: Evaluation of chromatography material. Peak Area (a), Retention Factor k (b) and Signal to 
noise ratio (c) was calculated for 89 selected metabolite standards (Appendix Table A-2). The standard 
compounds were analyzed as mixture at a concentration of 100 uM each. Number n=x indicates the 
number of detected metabolites for each method. 
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1.4.2 Method optimization for HILIC chromatography 
Based on the above described material evaluation we decided to further work 
with HILIC chromatography (BEH Amide) for the analysis of polar 
metabolites and attempted to optimize the chromatographic conditions for 
this material. The most critical parameter during this process was to find an 
optimal concentration range of ammonium acetate. This salt is essential for 
analyte retention on the HILIC column but high concentrations are unwanted 
because of ion suppression effects. Many standard metabolites were clearly 
visible in the extracted ion chromatograms (EIC) but not in the base peak 
intensity chromatogram (BPI) when 10 mM ammonium acetate was added to 
the elution buffer (Figure 1.2, right panel). This concentration range was 
recommended for normal flow HILIC LCMS by the manufacturer but the 
absence of metabolite signals in the BPI indicates ion suppression effects.  
 
Figure 1.2: Ion suppression and retention time of HILIC chromatography is affected by the ammonium 
acetate (NH4Ac) concentration in the elution solvents. Upper panel: Base peak intensity chromatograms 
(BPI) of 29 standard compounds. Each compound was injected at a concentration of 10 uM. Lower 
Panel: Extracted ion chromatograms of 7 selected standard metabolites. Left Panel: HILIC 
chromatography with 0.5 mM NH4Ac in the elution buffer, Right Panel: Chromatography with 10 mM 
NH4Ac. 
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When lowering the concentration of ammonium acetate in the elution buffer 
to 0.5 mM, the standard metabolite signals became clearly visible in the BPI 
(Figure 1.2, left panel). In addition, signal intensities for most analytes 
increased more than five-fold. The decrease in ammonium acetate 
concentration expectedly decreased the retention time of each standard 
compound. When the mixture of 29 standard metabolites contained low 
concentrations of ammonium acetate in the injection vial, nearly all 
metabolites eluted together with the solvent front (Figure 1.3, top panel). Only 
with the increase of ammonium acetate to a high concentration in the injection 
vial we could achieve a good chromatographic separation while keeping the 
ammonium acetate concentration low in the elution buffer (Figure 1.3, bottom 
panel).  
 
Figure 1.3 A high ammonium acetate (NH4Ac) concentration is essential for the binding and separation 
of analytes on the HILIC column (BEH amide). Extracted ion chromatograms (EIC) for 7 selected 
metabolites are shown. Injection solvent with different NH4Ac concentrations were used to dilute the 
metabolite mixture. Top EIC: 0.5 mM NH4Ac, middle EIC: 5 mM NH4Ac, bottom EIC: 50 mM NH4Ac. 
The elution buffers contained 0.5 mM NH4Ac. 
 
Finally, we achieve a good compromise of low ion suppression and analyte 
retention by reducing the ammonium acetate concentration in the elution 
buffer while maintaining a high amount of ammonium acetate in the injection 
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solvent. For the analysis of nonpolar metabolites and lipids, we modified a 
reversed phase LCMS method based on (Castro-Perez et al., 2010). This 
method was originally developed for lipids and contains high concentrations 
of organic solvents in both elution buffers. We removed the organic solvent 
portion during the initial elution gradient in order to increase the 
chromatographic range for slightly hydrophobic substances. 
 
1.4.3 Characterization of standard compounds 
The final capillary LCMS methods for the analysis of polar and unpolar 
metabolomes are summarized in (Table 1.1). Both methods involve small 
particles with diametes below 2 um and are therefore suitable for ultrahigh 
pressure liquid chromatography (UHPLC). Each gradient is completed after 
only 14 (HILIC) or 20 (reversed phase) minutes and the methods can be used 
for high throughput analysis of about 100 (HILIC) or 72 (reversed phase) 
samples per day. We characterized the analytical performance of the two 
methods with 190 metabolite standards (Table 1.3). These standards were 
selected to cover a broad range of human metabolic pathways in the KEGG 
database (Ogata et al., 1999). Each standard metabolite was analyzed in 
dilution steps from 20 pmol to 0.2 fmol. Limit of detection (LOD) value for 
each substance was obtained by choosing the dilution step where no signal 
was observed or where the signal-to-noise ratio (SNR) was below 3.  
 
Table 1.1: Capillary LCMS method overview 
 
Method Conditions
Column material
Particle Diameter
Column length
Column diameter
Injection solvent (1:5 diluted w/ analyte)
Solvent A:
Solvent B:
MS polarity
Gradient conditions: Minutes Composition B [%]
Flow rate 
[ul/min] Minutes
Composition 
B [%]
Flow rate 
[ul/min]
0.00 90.0 6.0 0.00 0 4
10.00 50.0 4.0 10.00 100 3
12.00 50.0 4.0 15.00 100 3
12.01 90.0 4.0 15.01 0 3
14.00 90.0 4.0 20.00 0 3
Non-polar 
metabolome/lipidome
HSS T3 (Waters)
1.7 um
5 cm
200 um
Polar Metabolome
BEH Amide (Waters)
1.8 um
15 cm
200 um
negative positive
Solvent A
5 mM ammonium formate
90% isopropanol, 10% acetonitrile, 5 mM 
ammonium formate
90% acetonitrile, 9% methanol, 1% 
water, 50 mM ammonium acetate
0.5 mM ammonium acetate, pH 9
95% acetonitrile, 0.5 mM ammonium 
acetate, pH 9
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From the 190 metabolite standards, 167 could be detected at least at 20 pmol 
concentration. From these, 123 were well retained (k > 1) on the HILIC 
column and 56 on the reversed phase column. The high amount of 
metabolites with good separation efficiency on the HILIC column highlights 
the importance of a non-polar stationary phase for the analysis of central 
carbon metabolism. However, for most of the rather non-polar metabolites the 
reversed phase column is superior to the HILIC column (Figure 1.4). Very 
polar metabolites such as ADP-ribose retain on the HILIC column but elute 
within the void volume of the reversed phase column. Complementary, non-
polar compounds suchas taurocholic acid are only retained on the reversed 
phase column. For most of the metabolite standards, the theoretically 
calculated logP value determined the fate of the respective analyte on either 
of both columns (Table 1.2). Polar metabolites with logP below zero retained 
preferantially well on the HILIC column whereas non-polar compounds 
around and above zero retained better on the reveresed phase column.  
 
Figure 1.4: Comparison between a) HILIC and b) reversed phase chromatography based separation of 
Palmitoyl-CoA, Taurocholate and ADP-Ribose. Very polar ADP-ribose is well retained using HILIC 
material BEH amide but elutes within the void volumn of a reversed phase column. Complementary, 
taurocholic acid retains well on the reversed phase column but not on the HILIC column. Amphipathic 
Palmitoyl-CoA can be seperated on both types of chromatography.  
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From all 167 detected metabolites, 152 could be retained on either HILIC or 
reversed phase chromatography and both methods nicely complement each 
other. For 63% of the metabolite standards (102) we could measure limit of 
detection values (LOD) in the femtomolar range (Table 1.3). The achieved 
sensitivity in full scan mode is therefore comparable to contemporary 
targeted LCMS methods where triple quadrupole mass spectrometer and 
normal flow chromatography are used (Luo et al., 2007; Buescher et al., 2010). 
This improved sensitivity might allow for improved detection of unknown 
peaks in a metabolic profiling experiment while maintaining the sensitivity 
for a targeted metabolome quantification. Despite a relatively short running 
time and a fast gradient, the capillary LCMS methods provide a good 
chromatographic resolution. A challenge in metabolomics is the separation of 
biologically relevant isomers and mass spectrometry alone does not allow for 
unambiguous annotation of these compounds. Especially for central 
metabolism it is of importance to distiguish between different forms of sugar 
phosphates (Buescher et al., 2010). For most of the sugar phosphates such as 
glucose-6-phosphate, fructose-6-phosphate and mannose-6-phosphate, 
baseline separation can be nearly achieved by using HILIC chromatography 
(Figure 1.5).  
Table 1.2: Retention behaviour of compounds with different polarity on a HILIC or reversed phase 
capillary LC column. Retention factor k (migration distance of analyte compared to solvent front) is 
given for hydrophobic (LogP > 0) or polar (LogP < 0) metabolites. 
 
 
 
Name logP
k                  
HILIC
k             
Reversed Phase
2-Phenylacetamide 0.64 0.1 1.6
3-Methoxytyramine -0.04 0.2 1.1
4-Pyridoxate -0.08 0.0 1.2
Homogentisate 0.81 0.0 4.1
Indole-3-acetate 1.87 0.1 1.8
Melatonin 1.42 0.0 2.2
N-Acetylserotonin 0.98 0.0 1.5
N-Methyltryptamine 2.02 0.2 1.5
Phenylacetaldehyde 1.75 0.0 4.0
Taurocholate 0.79 0.0 3.6
ADP -1.65 3.9 0.0
ADP-ribose -1.8 2.7 0.0
Asparagine -3.36 2.3 0.1
Citrate -1.33 3.8 0.0
Ethanolamine phosphate -2.5 3.5 0.0
Fructose 6-phosphate -2.11 3.2 -0.1
GDP -1.51 4.3 -0.1
Glucarate -3.6 2.8 -0.1
Glutamate -3.54 2.3 0.1
Glyceraldehyde 3-phosphate -1.69 3.2 0.0
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Figure 1.5: Chromatographic performance of very polar metabolites on a capillary UPLC column filled 
with BEH amide particles. 4 pmol of each substance was injected on column. Biologically relevant 
hexose-phosphate isomers can be seperated from each other by chromatography. 
1.4.4 Application of capillary LCMS methods to metabolite extracts of low 
abundant biological material  
The focus of this study was to find a sensitive method for a comprehensive 
metabolomics analysis of low abundant biological material, for example from 
small biopsies (<5mg). In order to test the proposed methods with a real 
application, we demonstrate a metabolome and lipidome analysis from 
colorectal tissue. A low amount of fresh biopsies (3-5 mg) from surgically 
removed colon tissue was collected. Normal mucosa and cancer tissue were 
chosen to investigate metabolome differences between both disease states. 
Metabolome and lipidome extracts were prepared by using a single methanol 
extraction step (Römisch-Margl et al., 2011). Accurate masses were matched 
to the KEGG database for metabolites (Ogata et al., 1999) or to the HMDB 
database for lipids (Wishart et al., 2013). The HMDB database was filtered for 
the super class „lipids“ prior to the search. 378 masses of the HILIC and 107 
masses of the reversed phase method could be annotated to 845 unique 
metabolite masses in the KEGG database. Additionally, 102 masses in the 
HILIC dataset and 688 in the reversed phase dataset were annotated to the 
lipid subset of the HMDB database, (Figure 1.6). Together, these results again 
demonstrate the complementarity of both methods for the analysis of polar 
metabolomes using HILIC and nonpolar metabolomes and lipidomes using 
reversed phase capillary chromatography based LCMS.  
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For the analysis of metabolomics data, especially for a non-targeted 
experiment, it is often desirable to interpret the data on the basis of altered 
metabolic pathways. To further characterize the annotated metabolome space 
in both of our methods, we investigated the coverage of metabolites in human 
metabolic pathways of the KEGG database (Ogata et al., 1999) (Figure 1.7). 
Except for the glycan biosynthesis pathway, metabolites of all pathways could 
be annotated. Notably, most of the metabolites involved in carbohydrate, 
energy, amino acid and nucleotide metabolism were annotated only in the 
HILIC dataset whereas metabolites found in the reversed phase dataset were 
more present in lipid metabolism. For each of these tissue groups (normal 
mucosa and cancer) we collected 5 replicates to investigate the biological 
variance. In order to test the technical robustness of the method, we created a 
pool sample from all extracts and injected this sample after every 6th LCMS 
run. Additionally, each sample was analyzed in three technical replicates. The 
median relative standard deviation (RSD) value for the annotated metabolites 
in the pool sample was 15.1% for the HILIC and 22.4% for the reversed phase 
method (Figure 1.8). Both methods provide therefore good overall technical 
reproducibility.  
 
Figure 1.6: Retention behaviour of a colorectal tissue metabolome (red, squares) and lipidome (blue, 
circles). 100 metabolite/lipid extracts from colorectal normal mucosa or cancer tissue were analyzed on 
the HILIC (a) or reversed phase (b) capillary LCMS system. Exact masses of a XCMS processed peak 
table were annotated as metabolites using the KEGG database (Ogata et al., 1999) or as lipids using the 
human metabolome database (Wishart et al., 2013). 
 
0 500 1000 1500
2
3
4
5
6
7
8
9
10
m/z
R
et
en
ti
o
n
 T
im
e 
[m
in
]
0 500 1000 1500
2
4
6
8
10
12
14
16
18
20
m/z
R
et
en
ti
o
n
 T
im
e 
[m
in
]
a) b) 
 34 
 
Figure 1.7: Coverage of annotated metabolites from the human metabolic pathways of the KEGG 
database. Colored lines indicate enzymatic reactions and each color corresponds to a specific metabolic 
pathway cluster. Green: Lipid metabolism, Dark blue (middle): Carbohydrate metabolism, Purple: 
Energy metabolism, Yellow: Amino acid metabolism, Red: Nucleotide metabolism, Bright blue (upper 
left): Glycan biosynthesis. Red dots: Metabolites annotated in the HILIC dataset. Blue dots: Metabolites 
annotated in the reversed phase dataset. Gray dots: Metabolites not annotated. 
 
Figure 1.8: Relative standard deviations (RSD in %) of 330 annotated metabolites in the HILIC method 
(a) and 1100 annotated lipids of the reversed phase method (b). All: RSD values of all samples, Pool = 
Pooled sample from all extracts. N = normal mucosa, T = tumor. Numbers indicate the patient number. 
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C02370 
C00230 
C00156 C02949 C06671 C06387 
C03233 C04783 
C00512 C09819 
C05449 
C05337 C06670 
C03569 C07729 
C06322 
C09820 
C02371 
C00410 
C03205 
C05479 
C02140 
C16480 
C15808 
Steroid 
biosynthesis 
C01802 
C05108 C11455 
C05439 
Primary 
bile 
acid 
biosynthesis 
C05107 
C15816 
C06555 
C05441 C01694 
C06553 
C06554 
Methane 
metabolism 
C05437 
C05103 
C06102 
C04525 
C02378 
C06593 
C15777 
Fatty 
acid 
elongation 
C18218 
C00249 
C06790 
Chloroalkane 
and 
chloroalkene 
degradation 
C06791 
C11435 
C06789 
C05748 C05758 C05760 C05751 C05754 C04246 C05763 
C05761 C05755 C05745 
Butanoate 
metabolism C05752 C05749 C02527 C05223 C05764 
Lipoic 
acid 
metabolism 
C00418 
C00129 
C11453 C11811 
C01107 C01143 
C16236 
C00136 
C00877 
C05274 C01944 
C05271 C05275 
C05270 
C03221 C05276 
C01832 
C00371 C16428 C16238 C16239 C00725 C16237 C16424 
C07092 
C05440 C15778 
Caprolactam 
degradation 
C14144 
C11436 
C07093 
C00246 
C14143 
C04488 
C01080 
C04330 
C00876 C06792 
C04377 
C09821 
Drug 
metabolism 
-  
cytochrome 
P450 
Metabolism 
of 
xenobiotics 
by 
cytochrome 
P450 
Nitrotoluene 
degradation C09816 
C19944 
C06714 
C07111 
C01575 C16719 
C11348 
C04351 
Toluene 
degradation 
C07101 
C06730 C06729 
C07100 
C07479 
C06728 
C07478 C01542 
C00232 
C00633 
C06757 
C01468 
C06756 C01454 C06758 
C06677 
C03676 
C07103 
C02814 
C04793 
Drug 
metabolism 
-  
other 
enzymes 
C06600 C07102 
C01455 
C20199 
C06762 
C08301 C08300 C02765 
Ethylbenzene 
degradation 
C11354 
C06727 
C06760 
C04844 
C02526 C03589 
C07089 
C00596 
C00168 
C00149 
C00682 
C00042 
C01273 
C02124 
C06588 
Dioxin 
degradation 
C06589 
C02222 
C07099 
C02375 
C06329 C07097 
C00080 
C03453 
C00004 C00399 
C06321 
C02923 
C07087 
C02501 
C00180 
C06720 C06210 
C00090 
C07733 
C07732 
C07734 
C03586 
C14610 
C02480 
C07208 C07216 
C07213 C16476 
C07209 
C07212 C07214 
C07211 
Benzoate 
degradation 
C17268 
C07123 C00390 C00003 
C00080 
C06731 Xylene 
degradation C08062 C08060 C08061 
C07215 
C06090 
C11874 
C06089 
C11895 
C11894 
C11897 
C11878 
C11901 
C06069 
C06070 
C11522 
C17622 C01943 
C06071 
C15776 
C05427 
C11508 
C15883 
C15882 
C11887 
C11857 
C11700 
C11882 
C11899 
C11863 
C14151 
C05445 
C05444 
C03594 
C05452 
C05455 
C05451 
C05500 
C05443 
C05138 C01953 C01227 
C05502 
C01164 
C05501 
Steroid 
hormone 
biosynthesis 
C01189 C00187 C17339 
C05454 
C05453 
C01301 
C05446 
C05272 
C11437 
C05896 
C00154 C02593 
Biosynthesis 
of 
type 
II 
polyketide 
backbone 
C05273 
C00048 C00118 C00445 C00313 C00143 
C00033 
C00024 
C00022 
C00222 
C00566 
C00227 
C00234 
Citrate 
cycle 
(TCA 
cycle) 
C00058 
C00117 
C00798 
C00354 C00209 
C00149 
C00862 
C06547 C06793 C00158 C00036 
C01380 C06548 
Glyoxylate 
and 
dicarboxylate 
metabolism 
C00988 
C00236 C01182 
C00160 
C00122 
C19614 
C00083 
C00527 
C19615 
Cutin 
Carbon 
fixation 
pathways 
in 
prokaryotes 
C11434 
C05382 C00085 
C01274 
Carbon 
fixation 
in 
photosynthetic 
organisms 
C00279 C00447 
C01001 
C06753 Styrene degradation 
C06754 
C01213 
C06600 
C13632 
Chlorocyclohexane 
and 
chlorobenzene 
degradation 
C06599 
C06752 
C07085 
Oxidative 
phosphorylation 
C07084 
C13636 
C10700 
C00530 
C12836 
C01146 
C06755 C05379 C12833 C12835 C12834 
C00002 
C00080 
C00524 
C00080 
C00007 
C00080 
C00091 
C00026 
C00080 C00080 C00080 
C00479 
C00009 C00001 
DDT 
degradation 
C06638 
C06640 C04596 
C06636 C04623 C06637 
C06594 C06597 C07075 
C05946 
C13433 
C15857 
C08579 
C05625 
C02094 C06098 C08614 
C00521 
C19765 
Monoterpenoid 
biosynthesis 
C06099 
C19764 Limonene 
and 
pinene 
degradation 
C05421 
C11393 Sesquiterpenoid 
and 
triterpenoid 
biosynthesis 
C16143 C02004 
C03427 
C01500 C00353 
C17621 
C01414 
C02141 
C08830 
Insect 
hormone 
biosynthesis 
C01902 
C06308 
C02462 
C04432 
Zeatin 
biosynthesis 
C15545 
C03190 
C06076 
C01724 C01054 
C00235 C00341 
C03428 
C00751 
Terpenoid 
backbone 
biosynthesis 
Anthocyanin 
biosynthesis C13455 C13453 
Flavone 
and 
flavonol 
biosynthesis C15970 C06082 
C09699 C06394 C09629 C09621 
C16829 C00448 
C09704 
Selenocompound 
metabolism 
C00322 
C00993 
C01089 C06002 
C05688 
C05662 C01251 C04002 
C03460 
Cyanoamino 
acid 
metabolism 
C00060 
C00164 C00356 
C00207 
C00047 
C01732 
Tetracycline 
biosynthesis 
C19889 
C05556 
C00311 
C05668 C00894 C01013 
C06157 
C00417 
C01011 
Propanoate 
metabolism 
C02614 
C5-Branched 
dibasic 
acid 
metabolism 
C05989 
C06000 
Synthesis 
and 
degradation 
of 
ketone 
bodies 
C06001 C00133 
C01528 
C00827 
C05172 C00186 
C00041 
C19888 
C03082 
Alanine 
C19887 
C00683 
C19886 
C00049 
C00152 
Lysine 
biosynthesis 
Lysine 
degradation 
C00100 
C03344 
C00956 
C00163 
C00258 
C00041 C00036 C00049 
C00074 Aminobenzoate degradation 
C00022 
C06551 
C01182 
C00058 C00067 C00011 C00197 
C00231 
C01010 C06552 C00080 
C00199 
C07095 
C04832 
C00132 C01438 
C03434 
C02575 
C04729 
C02232 
C04706 
C05297 
C00846 
Naphthalene 
degradation 
C00468 C00280 C05300 C05290 
C00829 
C00535 C05294 C05295 C05141 C00951 
C07094 
C18231 
Atrazine 
degradation C03920 C03845 
C01561 
C14145 
C01673 
C04628 
C07712 
C06104 
C02647 
C10860 
C01851 
C02918 
C05843 
C03325 
C02090 C03170 
C02046 
C00006 
C05842 
C04778 C06399 
C03114 
C00194 
C05775 
C06408 
C00153 C00003 
C02946 
C00729 
Nicotinate 
and 
nicotinamide 
metabolism 
C00300 
C02305 
C03771 
C01043 
C00213 
C00791 
C00011 
D-Arginine 
and 
D-ornithine 
metabolism 
C02565 
C01185 
C06178 
C06179 
C03722 
C00783 
C05936 
C00857 C00253 
C00179 
C00086 
C00745 
C00792 
C00581 
C00436 
C01010 
C02714 
C00062 
C02723 
C06503 
Clavulanic 
acid 
biosynthesis 
C05773 
C16244 
C06504 C11545 
C11542 
C11543 
C01847 
C11641 
C00010 
C03677 
C05818 
C09107 
C00399 
Pantothenate 
and 
CoA 
biosynthesis 
C09024 
C00828 
C11680 
C02987 
C11691 
C03406 
C01134 C00522 C03492 C04352 C00864 
C18911 
C00882 
C06250 
C12455 
C01092 
C06181 
C19845 
Tropane 
Arginine 
and 
proline 
metabolism 
C00148 
C01157 
Biotin 
metabolism 
C00437 
C00173 
C01063 
C03912 
C06182 
C04281 
C01035 
C01165 
C00077 
C00134 
C00515 
C01110 
C03089 
C01416 
C06183 
C00750 
C03287 
C02656 
C00170 
C00763 
C01137 
C04188 
C00327 
C04582 
C01250 
C00169 
Nitrogen 
metabolism 
C05840 
C15699 
C15767 
C00315 
C05730 
C12448 
C15700 
C08276 
C06112 
C02282 
C00120 
C00819 
C05921 
C01672 
C00217 
C05552 
C20386 
C01037 
C20373 
D-Glutamine 
and 
D-glutamate 
metabolism 
C20376 
C20375 
C19846 C20378 C20377 
C01909 
C20374 
C01234 
C15651 C15606 
C06547 
Glucosinolate 
biosynthesis 
C00019 
C15650 
C00141 
C04411 
C06007 
C02504 
C04236 
C00183 
C00603 
C06006 
C00719 
Valine 
C00407 
C00671 
C00123 
C00233 
C00014 
C03539 
C00697 
C04133 
C00021 
C06010 
C13309 
C04272 
C00966 
C00576 
Valine 
C02059 
C00916 
C07083 C03112 
C01419 
Penicillin 
and 
cephalosporin 
biosynthesis 
beta-Lactam 
resistance 
C12831 
C00666 
C05557 C00601 
C00680 
C05947 
C12832 
C04421 
C05539 
C03069 
C03345 
C01242 
C03618 
Glycine 
C00177 
C00143 C05712 
C00065 
C00630 
C00736 
C02612 
C06565 
C13629 
Bisphenol 
degradation 
C06564 
C13624 
C02083 
C04405 
C04076 
C00450 
C03231 
C02512 
C04390 C03239 
C04092 
C00408 
C00449 
C03871 
C07086 
Cysteine 
and 
methionine 
metabolism 
C00073 
C19929 
C00624 
C00025 
C00097 
C00155 
C01180 
C20258 
C03972 
C00395 
C06231 
C06442 
C03283 
C04462 
C00441 
C00114 C02226 
C15979 
C15975 
C01026 
C05519 
C06032 
C02291 
C00109 
C00669 
C00334 
C00064 
C19673 C20372 
Glutathione 
metabolism 
C00051 
C01209 
C15980 
C01118 
C01102 
C01077 
C00263 
C02939 
C00037 
C05125 
C00213 
C15977 
C00188 
C00330 
C15563 
C18910 
C00044 
C18239 C05924 
C16356 
C00286 
C00499 
C05584 
C05587 
C05577 
C04043 
C05580 
C17938 
C07481 
Caffeine 
metabolism 
C16357 C07130 
C04185 
C00242 
C01693 
C00385 
C16358 
Tyrosine 
metabolism 
C02350 
C05604 
C00386 
C05578 
C00788 C03758 
C05579 
C00547 
C15556 
Riboflavin 
metabolism 
C17937 
C05583 
C13747 
C05588 
C16365 
C05589 
C16352 
C00387 
C00361 
C00655 
C00362 
C16353 
C07480 
C01762 
C00144 C00035 
Thiamine 
metabolism 
C01279 
C04327 
C04556 
C00068 
C01081 
C03028 
C04752 C00378 
C04294 
C05922 
C00534 
C16675 
C11437 
C00647 
C00250 
C00627 
C00268 
C00018 
C00314 
C00568 
C06054 
C11638 Vitamin 
B6 
metabolism 
C04807 
C07335 C03393 
C00921 
C06055 
C15815 
C05923 
C06148 
C20248 
C15813 
C15996 
C01268 
C01304 
C20239 
C15814 C15810 
C00272 
C01300 
C00847 
C04895 
Folate 
biosynthesis 
C00266 
C04874 
C04244 C03684 
C00234 C00415 C00143 C00445 C00101 
C00016 
C04454 
C00061 
C00255 
C04732 
C04332 
C09421 
C11816 
Indole 
alkaloid 
biosynthesis 
C09390 
Ubiquinone 
and 
other 
terpenoid-quinone 
biosynthesis 
C17554 
C17559 
C05807 
C17551 
C05848 
C00430 
C06171 
C06165 
C06174 
C00931 
C00748 
C01024 
Isoquinoline 
alkaloid 
biosynthesis 
C01516 
C00504 
C05316 
C05576 
C05247 
C05175 C05191 
C05189 
C05193 C05190 
C05194 
C05594 
C06163 
C05817 
C03160 
C02730 
C00885 
C02106 
C15547 
C05174 
C16519 
C03657 
C03309 
C17562 
C03741 
C07304 
C03470 
C17552 
C01852 
C17561 
C17560 
C09244 
C06167 
C00156 
C05178 C05179 C05220 C05322 
C16186 
C01103 
C00072 
C14899 
C03291 
Puromycin 
biosynthesis 
C00112 
C00705 
C00015 
Purine 
metabolism 
C05422 
C01041 
C07836 C05382 
C03373 C04376 
C11472 C15667 
C04640 
C05512 
C00147 
C00559 
C00046 
C00206 
C00360 
C00212 
C00131 
C00020 
C04734 
C03794 
C04823 
C00130 
C04677 C04751 
C00002 C00008 
C00099 
C00366 
C12248 
C02642 C11821 
C00262 
C01829 
C00822 
C00294 
C00429 
C00355 
beta-Alanine 
metabolism 
C00106 
C01262 
C00082 
C20249 
C00380 C20231 
C00105 C00299 
Biosynthesis 
of 
vancomycin 
group 
antibiotics 
C00239 
C00039 
C00475 C00055 
Pyrimidine 
metabolism 
C06160 
Phenylalanine 
C02465 C01060 C02515 
C00628 
C00826 
C00544 C01179 C05585 
C01061 
C00519 
C01678 
C20253 
C00254 
C00606 C00245 C05122 
C01036 
Benzoxazinoid 
biosynthesis 
C02700 
C00954 
C00331 
C00643 
C00078 C00398 
C00637 
C00593 
C05123 
C03175 
C00439 
C00506 
C03680 
C00251 
C01269 
C00097 
Tryptophan 
metabolism 
C01598 C00632 
C00978 
C05635 
C03227 
C00780 
C05634 
C00328 
C01161 
C06161 
C05176 
C05582 
C02167 
Acridone 
alkaloid 
biosynthesis 
C05202 
C02514 
C02105 
C05581 
C04302 
Taurine 
and 
hypotaurine 
metabolism 
C01302 C00108 
C01252 C00463 C01717 
C03506 
C06320 
C06407 
C05772 
C06319 
C06416 
C06406 C17401 
C16242 
C16243 
C05778 
C11539 
C11538 
C11540 
One 
carbon 
pool 
by 
folate 
C03516 
C04536 
C02139 
C00032 C02191 
C02880 
C11831 
C00440 
C01051 
C03479 
C02463 
C03263 
C00664 
C06507 
C06510 
C06509 
C01079 
C06508 
C06505 
C06506 
C05306 
Porphyrin 
and 
chlorophyll 
metabolism 
C16540 
C18151 
C16541 
C05307 
Histidine 
metabolism 
C02637 
C04409 
C00493 
C03824 
C00785 
Biosynthesis 
of 
siderophore 
group 
nonribosomal 
peptides 
C00151 
C00388 
C01929 
C02658 
C00135 
Sulfur 
metabolism 
C00726 
C00979 
C01346 C00460 
C00214 
C00365 
C00364 
C00423 
Phenylalanine 
metabolism 
Novobiocin 
biosynthesis 
C00059 
C00459 
C00079 C00166 
C00363 
C00957 
C05852 
C00053 C00224 
C00283 
C00094 
C05527 
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To further characterize the biological and technical reproducibility of both 
methods, we performed a between group analysis (BGA) on the annotated 
metabolome and lipidome data set (Culhane et al., 2002). BGA deals with a 
common problem in most omics datasets, where more number of variables 
than cases are available. Instead of decomposing the raw data matrix on each 
variable (metabolites), a predefined number of groups is used. The BGA was 
carried out based on principal components analysis (PCA) and the following 
seven groups were defined: Normal mucosa from four patients (N1, N2, N3, 
N4), tumor tissue from two patients (T1, T2), and the pool sample (Pool). The 
first BGA axis clearly discriminates between a normal mucosa and cancer 
cluster in both datasets, indicating that the highest variation in the 
metabolome and lipidome is explained by the difference between normal 
mucosa and cancer (Figure 1.9). The second axis discriminates between the 
two different tumor tissues whereas the four normal mucosa tissues cluster 
closely together, suggesting that the metabolome of normal mucosa between 
different patients is more homogenous than the metabolome between the two 
tumors. The pool sample cluster is located in the center of both axes and 
shows only little variation. Also, the technical replicates are very close 
together with a similiar small variation compared to the pool samples. Again 
this demonstrates a good technical robustness of both methods. Within the 
clusters, especially in the tumor 1 (T1), there is a clear intra-group variation 
observable which exceeds the technical variation. This phenomenon might 
reflect the fact that biopsies of colorectal tissue consist of a very heterogenous 
mixture of different cell types. Consequently, the metabolome of biopsies 
from the same region but not exactly the same location may vary. However, 
the clear separation of the cancer and normal mucosa clusters on the first axis 
indicates that the metabolome changes between normal cells and cancer cells 
are reflected well in the extracts of the tissue biopsies. 
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Figure 1.9: Between group analysis (BGA) of colorectal tissue metabolome using capillary HILIC LCMS 
(a) and lipidome using capillary RP LCMS (b). Score plots of the BGA are shown. Colors indicate each 
biopsy cohort (normal mucosa or tumor). Pool = Pooled sample from all extracts. N=normal mucosa, 
T=tumor. Numbers indicate the number of patient or biological replicate. Technical replicates are 
indicated by a unique symbol. 
 
1.5 Conclusion 
We present two methods based on capillary LCMS for a sensitive 
quantification of metabolome and lipidome extracts from a small amount of 
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biological sample. Two complementary methods were chosen to address the 
very heterogenous polarity nature of the metabolome. After testing different 
column chemistries, a HILIC method was chosen for very polar metabolites. 
For lipids and non polar metabolites a reversed phase method was employed. 
For 167 standard compounds we report limit of detection (LOD) values in the 
low picomolar to femtomolar range. As a result, our method is suitable for 
non-targeted metabolomics by covering a broad range of metabolite masses in 
full-scan mode while providing high sensitivity using capillary flow rates. 
The achieved sensitivity is comparable to contemporary targeted LCMS 
methods using triple quadrupole mass spectrometers and normal flow 
chromatography (Luo et al., 2007; Buescher et al., 2010). Because of UPLC 
particles with sizes below 2 !m and a fast chromatographic gradient, one 
analytical run takes only 14 minutes for the HILIC and 20 minutes for the 
reversed phase method. Despite such a fast gradient, a good chromatographic 
separation can still be achieved. We demonstrate the applicability of the 
presented method in a metabolomics scenario with metabolome and lipidome 
extracts of colorectal tissue biopsies where only minimal amounts of 
biological sample are available (< 5 mg tissue). About a half of the metabolites 
in the KEGG database and additionally about 700 lipids could be annotated 
based on their accurate mass. For most of the quantified metabolites we 
achieve good technical reproducibility as indicated by RSD values between 15 
and 20% RSD. We recommend the described set of capillary LCMS methods 
primarily for high-throughput metabolomics experiments relying on a few 
hundreds of low volume samples. As the methods feature low solvent 
consumption and perfect compatibility to nanoESI mass spectrometry 
platforms, as in use in proteomics, we recommend consideration of this 
methods also in cases where sample size does not matter but platform 
flexibility is an asset.  
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Table 1.3: Standard compound characteristics and performance on the negative mode hydrophilic 
interaction chromatography (HILIC (-)) and the positive mode reversed phase (RP (+)) method. LOD = 
limit of detection. tR = retention time, k = retention factor 𝑘 = !!!!!!!  with t0 = retention time of the solvent 
front. 
 
 
 
 
Name KEGG ID Formula Mass logP LOD tR k LOD tR k
1-Methylnicotinamide C02918 C7H9N2O 137.072 -3.72 200 fmol 1.7 0.2
1.3-Diaminopropane C00986 C3H10N2 74.0844 -1 20 pmol 5.1 2.4
2-Aminoethylphosphonate C03557 C2H8NO3P 125.024 -1.55 20 pmol 7.4 3.7 20 pmol 1.7 0.1
2-Deoxy-D-ribose 1-phosphate C00672 C5H11O7P 214.024 -2.14 200 fmol 6.2 2.9
2-Oxobutanoate C00109 C4H6O3 102.032 0.07 20 pmol 1.8 0.1 20 pmol 7.6 4.1
2-Oxoglutarate C00026 C5H6O5 146.022 -0.6 2 pmol 4.6 1.9
2-Phenylacetamide C02505 C8H9NO 135.068 0.64 2 pmol 1.7 0.1 20 fmol 3.9 1.6
2-Phospho-D-glycerate C00631 C3H7O7P 185.993 -2.24 20 pmol 7.2 3.5 20 pmol 1.5 0.0
2.3-Bisphospho-D-glycerate C01159 C3H8O10P2 265.959 -1.55 2 pmol 1.4 '0.1
3-Aminoisobutyric acid C05145 C4H9NO2 103.063 -2.97 2 pmol 4.8 2.0 2 pmol 1.6 0.1
3-Aminopropiononitrile C05670 C3H6N2 70.0531 -0.9
3-Hydroxy-L-kynurenine C03227 C10H12N2O4 224.08 -2.09 2 pmol 3.9 1.5 2 pmol 1.7 0.1
3-Hydroxybutanoate C01089 C4H8O3 104.047 -0.5 2 pmol 3.3 1.0
3-Methoxy-4-hydroxymandelate C05584 C9H10O5 198.053 0 200 fmol 1.6 0.0
3-Methoxytyramine C05587 C9H13NO2 167.095 -0.04 20 pmol 1.9 0.2 2 pmol 3.2 1.1
3-Ureidopropionate C02642 C4H8N2O3 132.054 -0.98 2 pmol 4.0 1.5
3.4-Dihydroxy-L-phenylalanine C00355 C9H11NO4 197.069 -2.32 20 pmol 4.3 1.7 2 pmol 1.7 0.2
3.4-Dihydroxymandelate C05580 C8H8O5 184.037 0.72 20 pmol 2.7 0.7 2 pmol 1.2 '0.2
4-Aminobutanoate C00334 C4H9NO2 103.063 -2.99 2 pmol 5.6 2.5 2 pmol 1.5 0.0
4-Pyridoxate C00847 C8H9NO4 183.053 -0.08 2 fmol 1.6 0.0 200 fmol 3.3 1.2
5-Amino-4-imidazolecarboxyamide C04051 C4H6N4O 126.054 -1.16 2 pmol 1.7 0.0 20 pmol 8.4 4.6
5-Diphosphomevalonate C01143 C6H14O10P2 308.006 -1.17 2 pmol 7.6 3.7 20 pmol 1.3 '0.1
5-Formyltetrahydrofolate C03479 C20H23N7O7 473.166 -0.46 0.2 fmol 5.6 2.5 0.2 fmol 3.4 1.3
5-Hydroxyindoleacetate C05635 C10H9NO3 191.058 1.28
5-Methoxyindoleacetate C05660 C11H11NO3 205.074 1.76
5-Methyltetrahydrofolate C00440 C20H25N7O6 459.187 -1.26 200 fmol 6.3 2.9 20 fmol 3.4 1.3
5-Phospho-alpha-D-ribose 1-diphosphateC00119 C5H13O14P3 389.952 -6 20 pmol 1.3 '0.1
5-Phosphomevalonate C01107 C6H13O7P 228.04 -2.18 2 pmol 6.4 3.0 20 pmol 1.7 0.1
6-Deoxy-L-galactose C01019 C6H12O5 164.069 -2.39 20 pmol 2.8 0.8
Acetoacetate C00164 C4H6O3 102.032 -0.47 20 pmol 2.8 0.8 2 pmol 7.6 4.1
Acetyl phosphate C00227 C2H5O5P 139.988 -0.92 200 fmol 5.7 2.5
Acetyl-CoA C00024 C23H38N7O17P3S 809.126 -0.58 2 fmol 6.1 2.8 200 fmol 3.4 1.3
Adenine C00147 C5H5N5 135.055 -0.38 20 pmol 7.2 3.5 2 pmol 2.1 0.4
Adenosine C00212 C10H13N5O4 267.097 -1.21 200 fmol 1.8 0.1 20 fmol 3.4 1.3
Adenosine 3.5-bisphosphate C00054 C10H15N5O10P2 427.029 -1.63 0.2 fmol 7.2 3.5 2 pmol 2.0 0.3
Adenylyl sulfate C00224 C10H14N5O10PS 427.02 -1.64 2 fmol 4.4 1.8
ADP C00008 C10H15N5O10P2 427.029 -1.65 20 pmol 7.9 3.9 2 pmol 1.6 0.0
ADP-ribose C00301 C15H23N5O14P2 559.072 -1.8 20 fmol 5.9 2.7 200 fmol 1.5 0.0
Adrenaline C00788 C9H13NO3 183.09 -0.82
Agmatine C00179 C5H14N4 130.122 -1.01
Alanine C00099 C3H7NO2 89.0477 -3.26 2 pmol 5.3 2.3 20 pmol 1.4 0.0
Alanine C00041 C3H7NO2 89.0477 -3.05 2 pmol 4.6 1.9 20 pmol 1.5 0.0
Allantoate C00499 C4H8N4O4 176.055 -2.12 200 fmol 4.5 1.8 0.2 fmol 7.0 3.7
Allantoin C02350 C4H6N4O3 158.044 -1.95 200 fmol 2.0 0.3
Arabinose C00259 C5H10O5 150.053 -1.9 2 pmol 3.1 0.9
Arabitol C00532 C5H12O5 152.069 -3.2 2 pmol 3.6 1.2 2 pmol 7.6 4.1
Ascorbate C00072 C6H8O6 176.032 -0.5 20 pmol 4.2 1.6
Asparagine C00152 C4H8N2O3 132.054 -3.36 200 fmol 5.3 2.3 2 pmol 1.6 0.1
Aspartate C00402 C4H7NO4 133.038 -3.52 2 fmol 5.7 2.5 200 fmol 1.3 '0.1
ATP C00002 C10H16N5O13P3 506.996 -0.84 200 fmol 7.3 3.6 20 pmol ## ###
Biocytin C05552 C16H28N4O4S 372.183 -0.69 20 fmol 4.6 1.9 20 fmol 3.5 1.3
Biotin C00120 C10H16N2O3S 244.088 0.39
Butanal C01412 C4H8O 72.0575 1.1 0.2 fmol 3.8 1.5
Butanoyl-CoA C00136 C25H42N7O17P3S 837.157 -0.22 200 fmol 5.5 2.4 2 pmol 3.7 1.5
Cadaverine C01672 C5H14N2 102.116 -0.27 20 pmol 2.6 0.7
cis-Aconitate C00417 C6H6O6 174.016 -0.41 0.2 fmol 6.3 2.9 0.2 fmol 2.1 0.4
HILIC (-) RP (+)Metabolite Information
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Citrate C00158 C6H8O7 192.027 -1.33 2 pmol 7.6 3.8 200 fmol 1.4 0.0
CoA C00010 C21H36N7O16P3S 767.115 -0.61 20 pmol 6.2 2.9 200 fmol 3.3 1.2
Coniferyl alcohol C00590 C10H12O3 180.079 1.51 2 pmol 1.7 0.1 20 pmol 4.4 1.9
Cysteamine C01678 C2H7NS 77.0299 0.01
Cysteine C00097 C3H7NO2S 121.02 -2.57 2 pmol 6.2 2.9 20 pmol 1.5 0.0
dADP C00206 C10H15N5O9P2 411.035 -1.57 200 fmol 6.8 3.2 2 pmol 2.1 0.4
dAMP C00360 C10H14N5O6P 331.068 -2.44 2 fmol 5.9 2.7 2 pmol 2.5 0.7
Decanoyl-CoA C05274 C31H54N7O17P3S 921.251 0.87 20 fmol 4.7 1.9 2 pmol 7.2 3.8
Deoxyadenosine C00559 C10H13N5O3 251.102 -0.95 200 fmol 1.7 0.1 20 fmol 3.4 1.3
Deoxyguanosine C00330 C10H13N5O4 267.097 -1.75 20 fmol 2.0 0.2 200 fmol 3.3 1.2
dGDP C00361 C10H15N5O10P2 427.029 -1.45 20 pmol 7.8 3.9 2 pmol 1.5 0.0
dGMP C00362 C10H14N5O7P 347.063 -1.87 0.2 fmol 6.5 3.1 2 pmol 1.8 0.2
dGTP C00286 C10H16N5O13P3 506.996 -0.61 0.2 fmol 8.1 4.1 2 pmol 1.4 0.0
Dihydrofolate C00415 C19H21N7O6 443.155 -3.2
Dihydroorotate C00337 C5H6N2O4 158.033 -1.7 20 pmol 6.6 3.4
Dimethylallyl diphosphate C00235 C5H12O7P2 246.006 0.3 0.2 fmol 6.2 2.9
Dopamine C03758 C8H11NO2 153.079 -0.4 20 pmol 2.0 0.3 20 pmol 3.3 1.2
Ethanolamine phosphate C00346 C2H8NO4P 141.019 -2.5 2 pmol 7.2 3.5 2 pmol 1.5 0.0
Ethylene glycol C01380 C2H6O2 62.0368
FMN C00061 C17H21N4O9P 456.105 -0.78 200 fmol 5.6 2.5 200 fmol 3.7 1.5
Fructose C00095 C6H12O6 180.063 -2.4 20 pmol 4.6 1.9 200 fmol 7.6 4.1
Fructose 1.6-bisphosphate C05378 C6H14O12P2 339.996 -1.53 2 pmol 7.6 3.8
Fructose 6-phosphate C05345 C6H13O9P 260.03 -2.11 0.2 fmol 6.7 3.2 20 pmol 1.4 +0.1
Fucose 1-phosphate C02985 C6H13O8P 244.035 -1.53 20 fmol 6.5 3.1
Fumarate C00122 C4H4O4 116.011 0.21 2 pmol 4.7 1.9 20 pmol 5.0 2.4
Galactose C00124 C6H12O6 180.063 -2.57 2 pmol 4.2 1.6
Galactose 1-phosphate C00446 C6H13O9P 260.03 -2 0.2 fmol 6.9 3.3
GDP C00035 C10H15N5O11P2 443.024 -1.51 2 pmol 8.5 4.3 200 fmol 1.4 +0.1
GDP-L-fucose C00325 C16H25N5O15P2 589.082 -1.69 2 fmol 6.6 3.1 200 fmol 1.5 0.0
GDP-mannose C00096 C16H25N5O16P2 605.077 -1.76 2 fmol 7.0 3.4 2 pmol 1.4 0.0
Gentisate aldehyde C05585 C7H6O3 138.032 1.02 20 fmol 1.6 0.0 20 pmol 4.3 1.8
Glucarate C00818 C6H10O8 210.038 -3.6 200 fmol 6.1 2.8 2 pmol 1.3 +0.1
Gluconic acid C00257 C6H12O7 196.058 -1.87 200 fmol 5.0 2.1 20 pmol 7.6 4.1
Glucosamine 6-phosphate C00352 C6H14NO8P 259.046 -2.6 20 pmol 7.4 3.6 2 pmol 1.4 0.0
Glucose C00031 C6H12O6 180.063 -2.57 2 pmol 4.2 1.6 20 pmol 1.5 0.0
Glucose 6-phosphate C00668 C6H13O9P 260.03 -2.06 0.2 fmol 7.1 3.4 2 pmol 4.2 1.8
Glucuronate C00191 C6H10O7 194.043 -2 20 pmol 5.6 2.5
Glutamate C00025 C5H9NO4 147.053 -3.54 20 fmol 5.3 2.3 2 pmol 1.6 0.1
Glutamine C00064 C5H10N2O3 146.069 -3.32 200 fmol 5.3 2.3 20 pmol 1.5 0.0
Glutaryl-CoA C00527 C26H42N7O19P3S 881.147 -0.48 20 fmol 6.8 3.3 20 fmol 3.4 1.3
Glyceraldehyde 3-phosphate C00118 C3H7O6P 169.998 -1.69 2 pmol 6.6 3.2 20 pmol 1.5 0.0
Glycerate C00258 C3H6O4 106.027 -1.72 20 fmol 3.8 1.4
Glycerol C00116 C3H8O3 92.0473 -1.93
Glycerol 3-phosphate C00093 C3H9O6P 172.014 -1.84 200 fmol 6.1 2.8 2 pmol 1.4 +0.1
Glycine C00037 C2H5NO2 75.032 -3.34 20 pmol 5.2 2.3 20 pmol 1.5 0.0
Glyoxylate C00048 C2H2O3 74.0004 -0.59 2 pmol 3.9 1.4
GTP C00044 C10H16N5O14P3 522.991 -0.63 200 fmol 8.2 4.1 2 pmol 1.3 +0.1
Guanine C00242 C5H5N5O 151.049 -0.9 20 pmol 5.1 2.2 20 pmol 1.3 +0.2
Guanosine C00387 C10H13N5O5 283.092 -2.06 200 fmol 3.0 0.9 20 pmol 2.8 0.8
Hexanoyl-CoA C05270 C27H46N7O17P3S 865.188 0.07 2 fmol 5.2 2.2 200 fmol 4.6 2.1
Homogentisate C00544 C8H8O4 168.042 0.81 2 pmol 1.7 0.0 0.2 fmol 7.6 4.1
Homovanillate C05582 C9H10O4 182.058 1.02 2 pmol 1.6 0.0
Hypoxanthine C00262 C5H4N4O 136.039 -0.55 200 fmol 1.8 0.1 200 fmol 2.1 0.4
IDP C00104 C10H14N4O11P2 428.013 -2.47 20 pmol 7.6 3.7 2 pmol 1.4 0.0
IMP C00130 C10H16N5O12P3 491.001 -0.66 20 pmol 7.4 3.7
Indole-3-acetate C00954 C10H9NO2 175.063 1.87 200 fmol 1.8 0.1 200 fmol 4.3 1.8
Inosine C00294 C10H12N4O5 268.081 -1.87 20 fmol 1.9 0.2 20 pmol 2.7 0.8
Inositol C00137 C6H12O6 180.063 -2.08 200 fmol 6.3 3.0
Isocitrate C00311 C6H8O7 192.027 -0.35 2 pmol 7.0 3.4 2 pmol 1.4 +0.1
Isopentenyl diphosphate C00129 C5H12O7P2 246.006 0.04 200 fmol 6.2 2.9 2 pmol 2.0 0.3
Metabolite Information HILIC (-) RP (+)
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ITP C00081 C10H15N4O14P3 507.98 -0.67 20 pmol 8.3 4.2 200 fmol 1.3 !0.1
Lactose C00243 C12H22O11 342.116 -5.03 20 fmol 6.4 3.0
Lauroyl-CoA C01832 C33H58N7O17P3S 949.282 1.35 20 fmol 4.5 1.8 2 pmol 7.9 4.2
Malate C00149 C4H6O5 134.022 -0.87 0.2 fmol 5.5 2.5
Malonate C00383 C3H4O4 104.011 -0.6 20 fmol 5.4 2.4 20 pmol ## ###
Malonyl-CoA C00083 C24H38N7O19P3S 853.116 -0.62 200 fmol 6.9 3.3 2 pmol 3.3 1.2
Maltose C00208 C12H22O11 342.116 -5.03 0.2 fmol 6.1 2.8
Mannitol C00392 C6H14O6 182.079 -2.68 20 fmol 4.2 1.6 20 pmol 1.5 0.0
Mannose C00159 C6H12O6 180.063 -2.57 200 fmol 6.4 3.0 200 fmol 7.6 4.1
Mannose 1-phosphate C00636 C6H13O9P 260.03 -2 0.2 fmol 6.9 3.3 2 pmol 1.5 0.0
Mannose 6-phosphate C00275 C6H13O9P 260.03 -2.06 200 fmol 6.9 3.3 20 pmol 1.7 0.1
Melatonin C01598 C13H16N2O2 232.121 1.42 200 fmol 1.6 0.0 20 fmol 4.9 2.2
Methylglyoxal C00546 C3H4O2 72.0211 -0.38 200 fmol 2.8 0.8
Methylmalonate C02170 C4H6O4 118.027 0.17 20 pmol 4.8 2.0 20 pmol 3.4 1.3
N-(L-Arginino)succinate C03406 C10H18N4O6 290.123 -3.25 20 fmol 7.2 3.5 200 fmol 1.4 0.0
N-Acetyl-D-glucosamine C00140 C8H15NO6 221.09 -2.6 200 fmol 3.2 1.0 2 pmol 1.5 0.0
N-Acetyl-L-aspartate C01042 C6H9NO5 175.048 -0.79 2 fmol 5.3 2.3 2 pmol 1.4 !0.1
N-Acetylneuraminate C00270 C11H19NO9 309.106 -2.78 2 fmol 4.9 2.1 2 pmol 1.5 0.0
N-Acetylputrescine C02714 C6H14N2O 130.111 -0.84 2 pmol 1.7 0.2
N-Acetylserotonin C00978 C12H14N2O2 218.106 0.98 200 fmol 1.7 0.0 200 fmol 3.8 1.5
N-Methylhistamine C05127 C6H11N3 125.095 -0.57 20 pmol 5.7 2.6 20 pmol 2.0 0.4
N-Methylserotonin C06212 C11H14N2O 190.111 1.55 20 pmol 2.0 0.3 200 fmol 3.4 1.2
N-Methyltryptamine C06213 C11H14N2 174.116 2.02 20 pmol 1.9 0.2 200 fmol 3.8 1.5
NADH C00004 C21H29N7O14P2 665.125 -1.45 20 fmol 5.4 2.4 2 pmol 2.1 0.4
Noradrenaline C00547 C8H11NO3 169.074 -1.4
Normetanephrine C05589 C9H13NO3 183.09 -0.71 2 pmol 2.0 0.2 2 pmol 1.7 0.1
Octanoyl-CoA C01944 C29H50N7O17P3S 893.22 -3 2 pmol 4.9 2.1 2 pmol 6.2 3.1
Orotate C00295 C5H4N2O4 156.017 -0.89 20 fmol 2.6 0.6 20 pmol 6.7 3.5
Palmitoyl-CoA C00154 C37H66N7O17P3S 1005.34 2.35 200 fmol 4.5 1.8 20 pmol 9.1 5.0
Phenethylamine C05332 C8H11N 121.089 1.41 200 fmol 3.4 1.3
Phenylacetaldehyde C00601 C8H8O 120.058 1.75 2 pmol 1.6 0.0 0.2 fmol 7.6 4.0
Putrescine C00134 C4H12N2 88.1 -0.98 20 pmol 4.2 1.8
Pyridoxal C00250 C8H9NO3 167.058 0.02 20 fmol 1.8 0.1 200 fmol 2.1 0.4
Pyridoxal phosphate C00018 C8H10NO6P 247.025 -0.55 200 fmol 6.2 2.9 200 fmol 2.3 0.5
Pyridoxamine C00534 C8H12N2O2 168.09 -1.23 200 fmol 3.9 1.4 2 pmol 1.8 0.2
Pyruvate C00022 C3H4O3 88.016 -0.38 20 pmol 2.4 0.5 20 pmol 1.5 0.0
quinone C00472 C6H4O2 108.021 0.21 20 pmol 7.6 4.1
Raffinose C00492 C18H32O16 504.169 -3.36 2 fmol 7.8 3.8 2 pmol 1.5 0.0
Ribitol C00474 C5H12O5 152.069 -2.53 2 pmol 2.9 0.8
Riboflavin C00255 C17H20N4O6 376.138 -1.05 200 fmol 1.2 -0.2 200 fmol 1.4 !0.1
Ribose C00121 C5H10O5 150.053 -2.65 20 pmol 2.0 0.3
Ribose 1-phosphate C00620 C5H11O8P 230.019 -2.04 2 pmol 6.4 3.0
Ribose 5-phosphate C00117 C5H11O8P 230.019 -2.07 2 pmol 6.5 3.1
Ribulose 5-phosphate C00199 C5H11O8P 230.019 -2.07 200 fmol 6.1 2.8 20 pmol 1.7 0.2
Selenate C05697 H2SeO4 145.912
Serine C00740 C3H7NO3 105.043 -3.42 200 fmol 5.2 2.2
Serine C00065 C3H7NO3 105.043 -3.42 200 fmol 5.3 2.3 20 pmol 1.5 0.0
Sinapyl alcohol C02325 C11H14O4 210.089 1.36 20 pmol 4.5 1.8
Sorbitol C00794 C6H14O6 182.079 -2.68 20 fmol 4.1 1.5 20 pmol 1.5 0.0
Sorbitol 6-phosphate C01096 C6H15O9P 262.045 -2.32 200 fmol 6.9 3.3 2 pmol 1.4 !0.1
Spermidine C00315 C7H19N3 145.158 -0.62
Spermine C00750 C10H26N4 202.216 -0.66
Succinate C00042 C4H6O4 118.027 -0.53 2 pmol 5.1 2.2
Succinate semialdehyde C00232 C4H6O3 102.032 -0.47 200 fmol 4.5 1.8
Succinyl-CoA C00091 C25H40N7O19P3S 867.131 -6.7 200 fmol 6.9 3.3 200 fmol 3.4 1.3
Sucrose C00089 C12H22O11 342.116 -2.63 0.2 fmol 5.5 2.4 20 pmol 1.5 0.0
Sulfite C00094 H2SO3 81.9725 -2.7 20 pmol 1.7 0.1
Taurine C00245 C2H7NO3S 125.015 -2.19 200 fmol 4.0 1.5 2 pmol 1.6 0.1
Taurocholate C05122 C26H45NO7S 515.292 0.79 20 fmol 1.6 0.0 200 fmol 7.0 3.6
Tetradecanoyl-CoA C02593 C35H62N7O17P3S 977.314 1.84 20 fmol 4.6 1.9 2 pmol 8.5 4.6
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Tetrahydrofolate C00101 C19H23N7O6 445.171 -1.45
Thiamin diphosphate C00068 C12H19N4O7P2S 425.045 -0.1 20 pmol 9.1 4.7 20 pmol 2.1 0.4
Thiamin monophosphate C01081 C12H18N4O4PS 345.079 -1.68 20 pmol 7.8 3.9 20 pmol 1.7 0.1
Thiamine C00378 C12H17N4OS 265.112 -2.11 2 pmol 3.6 1.2 200 fmol 3.3 1.2
Trehalose C01083 C12H22O11 342.116 -2.98 0.2 fmol 6.3 2.9
Trypanothione disulfide C03170 C27H47N9O10S2 721.289 2 pmol 10.4 5.5 20 pmol 2.0 0.4
Tryptamine C00398 C10H12N2 160.1 1.21
Tryptophan C00078 C11H12N2O2 204.09 -1.1 200 fmol 2.1 0.3 200 fmol 3.4 1.3
Tyramine C00483 C8H11NO 137.084 -0.14 2 pmol 2.0 0.2 2 pmol 2.2 0.5
Tyrosine C00082 C9H11NO3 181.074 -2.39 200 fmol 4.0 1.5 2 pmol 1.7 0.1
UDP-D-galactose C00052 C15H24N2O17P2 566.055 -6.5 2 fmol 6.4 3.0 2 pmol 1.4 (0.1
UDP-glucuronate C00167 C15H22N2O18P2 580.034 -1.21 2 fmol 7.1 3.4 2 pmol 1.4 (0.1
Urate C00366 C5H4N4O3 168.028 -1.12 0.2 fmol 7.6 4.0
Urea C00086 CH4N2O 60.0324 -1.78
Xanthine C00385 C5H4N4O2 152.033 -0.65 2 pmol 4.6 1.9
Xylitol C00379 C5H12O5 152.069 -3.2 2 pmol 3.6 1.3
Xylose C00181 C5H10O5 150.053 -2.57
Metabolite Information HILIC (-) RP (+)
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2.1 Abstract 
Raw data processing, i.e. the extraction of compound identities and 
quantities, is a very important task in untargeted metabolomics. Coupled to 
high accuracy liquid chromatography mass spectrometry (LCMS) data, a vast 
amount of data is accumulated and file sizes approaching gigabyte 
dimensions are typically achieved with current instruments. In order to 
compare different LCMS experiments, a data reduction workflow to reduce 
complexity is essential. The aim of data processing typically involves the 
retrieval of mass-to-charge, retention time and ion intensity peaks. Current 
data processing tools focus on a peak detection strategy where initially each 
LCMS run is treated independently from each other. Subsequent data 
processing for the alignment of different samples is then calculated on 
reduced peak tables. In this work we describe a novel approach that involves 
the merging of all LCMS datasets of a given experiment as a first step of raw 
data processing. The merged LCMS dataset is reduced in size because it 
contains an overlay and the sum of ion intensities from all LCMS runs. Peak 
detection is then performed only on this merged dataset and quantification of 
the signals in each sample is guided by the peak location in the merged data. 
We compared our data processing strategy with algorithms of the 
Bioconductor package XCMS and demonstrate that a large amount of low 
abundant signals can only be detected from the merged data while they are 
missed during peak detection in single LCMS runs. 
2.2 Introduction 
In a untargeted LCMS based metabolomics experiment, raw data processing 
is the first fundamental part in the computational pipeline and a couple of 
software tools have been developed for this purpose (Sugimoto et al., 2012). 
The core function of LCMS raw data processing is to identify and quantify as 
much metabolites as possible in a series of data sets. This task typically 
consists of three steps: 1) Peak detection in a 3-dimensional space: mass-to-
charge ratio (m/z), retention time (RT) and ion intensity. 2) Linear or non-
linear transformation of the retention time. This step is important because 
analytical variations in the chromatographic dimension usually cause shifts in 
the elution profile. 3) Alignment of the identified features (m/z and RT 
location) across different LCMS runs. As a result, the algorithm produces a 
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data matrix that can be used for statistical analyses and biological 
interpretation. A good raw data processing algorithm should have the 
following characteristics: 1) It is sensitive enough to detect even the smallest 
peaks and 2) Is robust against false detection of noise (Tautenhahn et al., 
2008).  
A critical point in LCMS raw data processing is the detection of low abundant 
signals. Typically, the dynamic range of ion intensities is quite broad and low 
abundant features are characterised by a low signal-to-noise ratio (SNR). In 
most metabolomics experiments, a multitude of LCMS runs from a similar 
biological matrix is analysed. It is expected that each metabolite signal is 
always located at the same position, i.e. has always the same RT and m/z 
value. We therefore hypothesized that overlaying of the raw data signals from 
multiple LCMS runs leads to a better SNR and eventually might improve the 
detection of low abundant metabolites. 
2.3 Experimental Section 
Colorectal biopsy samples were collected from surgically removed colon. The 
biopsies with fresh weights between 3 and 5 mg were snap frozen in liquid 
nitrogen and stored at -80°C until use. 100 µL methanol per 3 mg biopsy was 
added and the tissue was disrupted using a glass homogenizer. Debris was 
removed and the extract was diluted 1:5 with 5 mM ammonium formiate for 
reversed phase LCMS. For HILIC LCMS, the extract was dried under vacuum 
and resuspended with injection solution prior to LCMS analysis (90% 
acetonitrile, 9% methanol, 1% water, 50 mM ammonium acetate at pH 9). For 
the reversed phase method a 50 mm self packed capillary column with a 
internal diameter of 200 µm was used. The chromatography material HSS T3 
(Waters Corp., Miford USA) was filled into the capillary. We used a 10 min 
gradient from 5 mM ammonium acetate to 90% isopropanol/10% acetonitrile 
with a flow rate decreasing linearly from 5 to 3 µl/min. For the HILIC method 
we used also a self packed capillary column with the following properties: 15 
mm column length, BEH amide material (Waters Corp.), 200 µm inner 
diameter. The elution buffers consisted of A: water and B: 95% acetonitrile 
and both buffers contained 0.5 mM ammonium acetate at pH 9. The gradient 
was 90% B to 50% B in 10 minutes using a linearly decreasing flow rate from 6 
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to 4 µl/min. For the analysis of the biopsy samples, we collected 30 normal 
mucosa or cancer biopsies. These samples were analysed in triplicates and 
additionally a pool sample from the 30 extracts was injected 10 times. In total, 
a set of 100 LCMS runs was created. The MS data was acquired on a Synapt 
G2 in MSE negative (HILIC) or positive (reversed phase) mode. The low 
collision energy full scan channel was converted to centroid and vendor 
independent netCDF format using MassLynx 4.1 and the integrated 
conversion software DataBridge (Waters). To compare our algorithms with 
xcms algorithms, netCDF data were processed with xcms (Smith et al., 2006) 
using the matchedFilter algorithm (fwhm = 4, snthresh = 5, step = 0.02, mzdiff 
= 0, max = 50) or the centWave algorithm (ppm = 25, snthresh = 5, 
peakwidth=c(1,60)). The retention time of the peaks were aligned using the 
obi-warp algoritm with parameters profStep=1 and distFunc="cor". Peak 
tables were grouped using the parameters mzwid = 0.01 and bw = 2. To 
annotate C13 isotopes we used the CAMERA package (Kuhl et al., 2012). For 
this purpose, the functions “groupFWHM” and “findIsotopes” were used. To 
evaluate the algorithm performance with differently sized sets of LCMS runs, 
the complete workflow (xcms and CAMERA) was applied to 2, 5, 10, 20, 50 or 
100 samples. The selection was made randomly with the exception of one 
pool sample which was included every time. This pool sample was used as 
the reference for retention time alignment. 
2.4  Theory 
Full scan high accuracy mass spectrometry, coupled to chromatography are 
powerful and popular methods to profile hundreds to thousands of 
metabolites in biological samples. Such an untargeted experimental strategy 
requires algorithms capable to reliably identify and quantify a large amount 
of signals. Typically, a single full scan LCMS metabolomics dataset consists of 
hundred thousands data points and data sizes around 100 MB or more. For 
the analysis of multiple metabolomics datasets such as comparison of 
different biological conditions there is a need of data reduction in order to 
process several to hundreds of LCMS datasets. A common strategy to reduce 
required memory space in full scan LCMS data processing is to generate 
retention time/mass-to-charge peak lists as a first step (Sugimoto et al., 2012). 
In order to detect signals with a very low signal intensity and poor signal-to-
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noise ratio (SNR) the algorithm paramaters are defined very generously, i.e. 
the SNR threshold is set to a very low value. The disadvantage of this 
approach is to risk the detection of a high amount of false positive peaks. The 
basic idea behind the here presented study is based on the fact that LCMS 
datasets are fairly well reproducible in the mz and retention time locations of 
every analyte. While low abundant mass signals with low SNR values in a 
single LCMS run are difficult to be reliably detected, a combined analysis of 
all signals from multiple LCMS runs might decrease the amount of random 
noise and improve ion statistics (Figure 2.1). An algorithm with the ability to 
detect peaks on a dataset which combines ions of multiple LCMS runs could 
therefore potentially detect low abundant signals with a higher robustness 
compared to algorithms where peaks are detected on single LCMS runs alone. 
Here we will describe our raw data processing approach. It aims for the 
combination of the mass and retention time dimension of multiple LCMS 
runs. Using this approach we generate overlays of the mass or retention time 
dimension of all samples. The peak detection process (mass peaks or retention 
time peaks) is carried out on these overlays. All described algorithms were 
developed in the open source environment R (R Development Core Team, 
2013) or modified using existing R and Bioconductor packages (Du et al., 
2006; Smith et al., 2006; Tautenhahn et al., 2008). We implemented the 
presented workflows in a new open source R package called cosmiq (Combine 
single masses into quantities). The package was designed to support the 
xcmsSet class and can be therefore used together with other functions built 
around the xcms package. The five steps of the processing strategy of cosmiq 
are shown in Figure 2.2. 
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Figure 2.1: Example region of metabolomics raw data based on high accuracy mass LCMS. The masses 
range between 650.5 and 650.7 Da is shown. Data were recorded in centroid mode. Centroids of a single 
(a) or an overlay of the centroids of 102 LCMS runs (b) are shown. The color indicates the centroid 
intensity and the colorbar is displayed along a log(10) scale. The retention time of the 102 LCMS runs in 
b) were aligned before data were plotted. Arrows indicate dense regions of centroids where a mz/RT 
peak is clearly visible by visual inspection. 
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Figure 2.2: The raw data processing pipeline of cosmiq. 
1. Raw data!
Combination of mass spectra"
"
2. Combined mass spectrum!
Detection of relevant masses using 
continuous wavelet transformation 
(CWT)."
3. Extracted ion chromatogram 
(EIC)!
Generation of EIC for each detected 
mass bin."
4. Combined EIC"
Retention time alignment and 
combination of EICs from all 
samples. !
Chromatographic peak detection 
with CWT."
5. Peak quantification"
Search for mz/RT location in raw 
data. Calculate peak area."
m/z  ✔ "
RT peak detection ✔ "
m/z"
Retention 
time (RT)"
RT alignment ✔ "
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Figure 2.3:  Step 1: Combination of mass spectra for the detection of relevant mass bins. Raw data of a 
single LCMS run is shown around the region of the metabolites glutamine and glutamic acid (a) and a 
close-up of the region around glutamic acid (c). The combined mass spectrum of the same sample and 
the regions as seen in a) and c) is shown in b) and d), respectively. The intensity of the raw data 
centroids is indicated by a grayscale color. The colorbar represents log(10) transformed intensities. 
2.4.1 Step 1: Combination of mass spectra 
The first two processing steps search for relevant mass bins in the dataset. 
Binning of the mass dimension was criticised because it is difficult to select an 
optimal bin size without a priori information of occurring masses (Aberg et 
al., 2008). In order to select for optimal bins, we first calculate a combined 
spectrum. This approach of overlaying and summing intensities of single 
scans together is prominent for applications in flow injection mass 
spectrometry and leads to improved ion statistics (Fuhrer et al., 2011). Mass 
spectra not only from all scans of a single LCMS run alone are combined but 
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from all acquired datasets. As a result, signal to noise ratio increases for each 
additional LCMS run (Figure 2.3). For example, high abundant metabolites 
with intensities around 10000 counts like glutamine and glutamic acid are 
clearly visible in the raw centroid data as well as in the combined mass 
spectrum (Fig 2.3 b). Low abundant masses around 100 counts are difficult to 
spot in the raw LCMS data but show a clear peak in the combined mass 
spectrum (red and green circle, Figure 2.3 d). 
 
2.4.2 Step 2: Detection of relevant masses 
Based on this combined mass spectrum we then determine location and 
boundary of each mass. A peak detection algorithm based on continuous 
wavelet transformation (CWT) is used for this step (modified from Du et al., 
2006). Peak detection based on CWT has the advantage that a sliding scale of 
wavelets instead of a single filter function with fixed wavelength is used 
(Tautenhahn, 2009). This allows for a flexible and automatic approximation of 
the peak width. As a result it is possible to locate both narrow and broad 
peaks within a given dynamic range. To detect the optimal peak locations, 
regional maxima on each scale of the CWT transformed data are calculated. 
The regional maxima on the scale with the highest intensity are selected as 
optimal peak locations (as described in Du et al., 2006). The adjacent local 
minima on the selected scale maximum are a good estimator of the real peak 
width (Tautenhahn, 2009). However, regional maxima in the CWT space are 
only a reliable indicator for a good peak location if there are no overlapping 
peaks in the dataset (Tautenhahn et al., 2008). The scale with the highest 
intensity detects all overlapping peaks as a single one (Figure 2.4 b). In order 
to test if there exist two or more overlapping peaks we examine the raw data 
at each position where an optimal peak was located by the regional CWT 
maximum. The width of the suspected original peak at a selected intensity 
treshhold (e.g. width at half peak maximum) is investigated. If there exist 
overlapping peaks, the width of the peak is divided. The new optimal CWT 
scale is then estimated as the width of the broadest overlapping peak (Figure 
2.4 d). 
 51 
 
Figure 2.4: Step 2 and Step 4: Feature detection using continuous wavelet transformation (CWT). Close-
up of a combined mass spectrum between 746.5 and 747.8 Da (a). This spectrum was transformed with 
scales between 1 and 10 using CWT (b). Peak locations as indicated by local CWT scale maximum are 
shown as red dots. Local scale maxima overlaid to the raw data (c, red curves). The overlapping peaks 
between mz 747.5 and 747.6 are only resolved if the optimal scale in the region is approximated using 
the raw data (blue curves in d), blue dots in b), see text for details). 
2.4.3 Step 3: Generation and combination of extracted ion chromatograms 
Until now only the mz information was considered. In the following 
processing steps the chromatographic information will be added. For the 
comparison of different LCMS datasets it is important to consider RT shifts. 
746.6 746.8 747 747.2 747.4 747.6 747.8
0
1
2
3
x 10
6
Io
n
 I
n
te
n
si
ty
a)
C
W
T
 s
ca
le
b)
746.6 746.8 747 747.2 747.4 747.6
2
4
6
8
10
746.6 746.8 747 747.2 747.4 747.6
0
1
2
3
x 10
6
Io
n
 I
n
te
n
si
ty
c)
746.6 746.8 747 747.2 747.4 747.6
0
1
2
x 10
6
m/z
Io
n
 I
n
te
n
si
ty
d)
 52 
These shifts are typically caused by technical variations and need to be 
corrected before chromatographic peaks between different LCMS runs are 
aligned (Smith et al., 2013). For this purpose cosmiq implements the warping 
algorithm OBI-WARP which is included in the xcms package and can be 
directly applied on the raw data (Prince and Marcotte, 2006). For each 
detected mass in step 2 we calculate an extracted ion chromatogram (EIC). In 
order to determine the elution time for each detected mass, the EICs of every 
mass are combined between all acquired runs. Again, this combination 
approach aims for an improvement of the signal-to-noise ratio (SNR). As an 
example we demonstrate the detection of four hexose-phosphate isomers with 
the monoisotopic mass 259.0223 ([M-H] adduct, Figure 2.5). Before RT 
alignment, the EICs are highly dispersed along the RT axis (Figure 2.5a). After 
RT correction, the EICs between all the acquired LCMS runs are well aligned 
(Figure 2.5b). The monoisotopic peaks of the four isomers can be seen in one 
single EIC, but the signal is noisy (Figure 2.5c). The SNR of these four 
chromatographic peaks becomes better when all aligned EICs from Figure 
2.5b are combined (Figure 2.5e). This effect becomes more evident if the less 
abundant isotopic mass with one C(13) of the same molecule is investigated: 
The four isomer peaks are hardly distinguishable from the noise in a single 
LCMS run (Figure 2.5d) but become clearly visible in the combined EIC of all 
LCMS runs (Figure 2.5f). 
2.4.4 Step 4: Detection of chromatographic peaks 
Based on the combined EICs there is another peak detection step to be 
performed. The algorithm as described for the peak picking of m/z signals in 
Step 2 is used also for peak picking in the retention time domain. The final 
result is a peak table with location and boundaries of each mz/RT feature. 
This information will be further used to locate the relevant position in every 
single LCMS dataset in order to quantify sample specific feature intensities. 
Because the mz/RT features were detected on the combined mass spectra or 
EICs of all samples it is not necessary to align features between different 
LCMS runs as for the typical raw data processing workflow (Sugimoto et al., 
2012). Instead, a data matrix with intensity values for every mz/RT feature 
and every sample can be immediately calculated. 
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Figure 2.5: Step 4: Chromatographic peak detection using continuous wavelet transformation. Extracted 
ion chromatograms (EIC) are shown for 100 LCMS samples before (a) or after retention time alignment 
(b) Ion intensity for each sample is shown in grayscale intensity. c) EIC of a single LCMS sample 
showing the monoisotopic mass of hexose-phosphate (m/z 259.0223). e) Peak detection of the same 
mass and retention time window, but with a combined EIC of 100 LCMS runs. The EIC for the same 
molecule containing one C(13) isotope is show in d) for a single EIC and for the combined EIC in f). 
 
2.4.5 Step 5: Localisation and quantification of detected peaks 
With the information about their position in the combined datasets, each 
individual mz/RT feature is then located in the raw data. Due to the retention 
time correction, each feature is expected at the same RT position as in the 
combined EIC. However small shifts in retention time still occur for most of 
the peaks (See for example the EIC from sample 59 in Figure 1.5 b). In order to 
locate the correct position of each feature, the EIC of the selected mass is 
calculated for the whole retention time. This EIC is filtered with CWT using 
only the scale where the feature was optimally located on the combined EIC 
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maximum with the closest position to the expected retention time is chosen. 
Local minima to the maximum of the transformed data are selected as peak 
boundaries as suggested by (Tautenhahn, 2009) and the peak area is then 
calculated on the raw EIC. 
2.5 Results and Discussion 
2.5.1 Evaluation of different algorithms 
A peak list with intensity values for mz/RT features of every sample is 
produced as the output of the five data processing steps. A further step to 
deisotope peaks or annotate adducts is not included. As already mentioned, 
the cosmiq package is intended to provide alternative raw data preprocessing 
within a metabolomics workflow using R. Thus, other xcms based functions 
or packages can be used in combination with the processing pipeline of 
cosmiq. To evaluate our algorithms, we designed an experiment with the aim 
to test the significance of analysing multiple LCMS runs together. The main 
idea to develop cosmiq was to improve the detection of low abundant 
metabolites by combining the ion intensities of multiple LCMS runs before 
peak detection is performed. Our central hypothesis states that the more 
LCMS runs are added to the analysis, the more robust will be the detection of 
low abundant signals. We created two different metabolomics datasets for 
this testing purpose: One dataset using hydrophilic interaction 
chromatography (HILIC) for a polar metabolome and reversed phase 
chromatography (RP) for a lipidome analysis. Each dataset consists of 
capillary flow based LCMS analyses of colorectal tissue metabolite extracts. 30 
normal mucosa and cancer biopsies were collected and analysed in three 
technical replicates. Additionally, these 30 samples were collected together in 
a pool sample. This pool sample was injected 10 times and in total both 
datasets consist of 100 LCMS runs, each containing the analysis of a similar 
biological matrix. From these 100 LCMS runs we randomly selected 2, 5, 10, 
20, 50 or 100 for a joint data analysis. The LCMS analyses were done in full 
scan mode to allow for a non-targeted data acquisition. We compared the 
cosmiq workflow with two peak picking algorithms from the xcms package: 
matchedFilter and centWave (Smith et al., 2006; Tautenhahn et al., 2008). 
matchedFilter is the original algorithm of xcms and centWave was developed 
for high resolution centroid LCMS data. Both algorithms were tuned in a way 
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that low abundant signals with a poor SNR are considered (SNR threshold 5). 
Other peak detection parameters were tuned in order to reveal an equal 
amount of features for the analysis of five samples. The cosmiq parameters 
were tuned with a low SNR threshold (5) for the mass detection and a 
moderate SNR threshold (20) for the chromatographic peak detection step. 
The retention time parameters of the obtained peak lists were aligned using 
the obiwarp function. As the retention time alignment with cosmiq is also 
based on this algorithm, the time alignment step is identical in all three 
workflows. The final grouped peak list was used as basis for the evaluation 
process.  
2.5.2 Effectiveness of the different algorithms 
For a non-targeted metabolomics workflow it is difficult to assess the quality 
of raw data processing. Typical approaches use known metabolite standards 
as references (Nordström et al., 2006; Wei et al., 2011). Such an approach 
however is restricted to the interpretation of a small set of spiked analytes and 
not suitable to estimate the quality of thousands of annotated features. Other 
feature evaluation studies aimed for the calculation of precision and recall 
values as a information retrieval measure (Tautenhahn et al., 2008; Kenar et 
al., 2014). For these approaches it is necessary to define a robust ground truth 
set of features, which has to be recognized by the algorithms. One of these 
studies generated an artificial LCMS dataset using a simulator software, 
where the ground truth was retrieved from the simulator (Kenar et al., 2014). 
In another study the authors calculated a ground truth dataset based on an 
intersection peak list from different algorithms (Tautenhahn et al., 2008). For 
the evaluation of the feature detection quality of our dataset with 100 
samples, we included the package CAMERA to our workflow (Kuhl et al., 
2012). The main function of CAMERA is to deconvolve the feature list output 
of xcms and to annotate C(13) isotopes and adducts. Our assumption was that 
a good metabolomics data processing workflow reliably detects not only 
single masses, but identifies all connected isotope patterns. We therefore 
calculated the number of features which could be linked to an isotope pattern 
and compared it to the total number of detected features. The resulting ratio 
between 0 (no peak could be assigned to an isotope pattern) and 1 (all peaks 
were annotated within an isotope pattern) was used as quality measure. This 
 56 
approach has several advantages: 1) Every detected feature of the non-
targeted data processing is considered and therefore all low abundant signals. 
2) Real metabolomics data and no simulation data is used. With this measure 
we observed that the quality of the feature detection is independent of the 
amount of LCMS samples in the data processing pipeline (Figure 2.6 a and b). 
For both, the HILIC and the RP datasets we observe a relatively constant ratio 
of annotated isotopes compared to unannotated features by CAMERA. This 
result suggests that the detection of false positive features is independent of 
the amount of LCMS runs. For the HILIC measurement the ratio of isotope 
pattern/all peaks was between 0.3 and 0.35 for the cosmiq algorithm with a 
slight increase towards multiple LCMS runs. For both the matchedFilter and 
centWave it was around 0.1. For the RP dataset the ratio was around 0.45 for 
cosmiq, 0.25 for centWave and 0.2 for matchedFilter. Although this result 
suggests that cosmiq provides a better peak detection effectiveness compared 
to the xcms algorithms, we want to point out that the selection of data 
processing parameters were chosen quite unrestrictive in terms of SNR 
parameters. Therefore a high number of unspecific signals are detected and a 
low amount of isotope patterns has to be expected. The total amount of 
detected monoisotopic masses ([M]) was quite constant in the HILIC dataset 
when matchedFilter or centWave was used (Figure 2.6 c). In the RP dataset, 
the total number of [M] slightly increased from 2 to 10 LCMS runs but 
remained constant between 10 and 100 runs (Figure 2.6 d). Interestingly, the 
number of LCMS runs had an enormous impact on the amount of detected 
[M] when cosmiq was used for both HILIC and RP (Figure 2.6 c/d). For a 
small amount of LCMS runs (2-5), the number of [M] is minimally higher in 
the cosmiq dataset versus the xcms algorithms. However this number 
drastically increases almost ten-fold for the HILIC dataset and 4-fold for the 
RP dataset when 100 LCMS runs are processed. In summary, the addition of 
LCMS runs to the processing pipeline does not infer with the overall peak 
detection quality for none of the three algorithms. However, for the data 
processing with cosmiq the amount of detected monoisotopic peaks and 
therefore the amount of putative metabolites increases with the number of 
LCMS runs whereas the xcms algorithms always detects a constant amount of 
monoisotopic peaks irrespective of the number of LCMS runs. This result 
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indicates that the combination of LCMS runs with cosmiq can improve raw 
data processing in terms of an increased metabolite detection rate. 
 
Figure 2.6: Number of detected features and comparison of three different peak detection algorithms. 
Peak detection quality was calculated as the ratio of annotated isotopes/all peaks shown for a HILIC (a) 
and a RP dataset (b). Number of detected monoisotopic masses as calculated by the package CAMERA 
is shown for HILIC (c) and RP (d). 
 
2.5.3 Dynamic range of the detected metabolome 
An increased number of metabolite detection by cosmiq compared to the 
xcms algorithms can be explained by an improved detection of low abundant 
compounds. As illustrated in Figure 2.5 the combination of LCMS samples 
improves the signal to noise ratio of low abundant signals. Consequently, the 
metabolites which are missed by the xcms algorithms due to a poor SNR in 
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each sample, might be detected by cosmiq. In order to test this hypothesis, we 
investigated the dynamic range of the metabolome in each of our datasets. We 
matched all found monoisotopic masses to the human metabolome database 
(Wishart et al., 2013) and annotated metabolites within a mass accuracy of 
0.01 Da. The annotated metabolites were classified in three groups: 1) 
Detected by all algorithms, 2) detected by matchedFilter, centWave or both, 3) 
detected only by cosmiq. In order to investigate the effect of multiple LCMS 
runs on the annotation, we compared the lowest number (2) and the highest 
number of joined LCMS samples (100). 
For each of the annotated metabolites, we calculated the mean intensity 
values across every sample. For the metabolites detected by all algorithms 
there was a slight increase of annotated metabolites from 2 to 100 joined 
LCMS samples (Figure 2.7). For the HILIC dataset, 41 metabolites were 
detected in 2 and 49 metabolites in 100 LCMS runs, respectively. For the RP 
dataset there was an increase from 141 to 213 detected metabolites. 
Conversely, there was a slight decrease of annotated metabolites which were 
unique for the matchedFilter or centWave dataset: 91 to 84 for the HILIC 
dataset and 146 to 135 for the RP dataset, respectively. For the features which 
were uniquely detected with cosmiq there was a more than 4-fold increase of 
detected metabolites for both HILIC and RP. These numbers indicate again 
that multiple joined LCMS samples lead to an increased detection of 
metabolites in the data processing pipeline of cosmiq. Remarkably, not only 
the number of detected metabolites increases but also the dynamic range of 
intensities decreases for the metabolites which were only detected by cosmiq. 
If only 2 LCMS runs are considered, the interquartile range of peak intensities 
lies between 619 and 2774  for the HILIC dataset and between 1788 and 9812 
for the RP dataset. For 100 LCMS runs however, the interquartile range drops 
to 106/794 for HILIC and to 363/1326 for the RP data. The peak intensity 
range of solely cosmiq specific metabolites is therefore up to ten times lower 
compared to the matchedFilter or centWave specific metabolites. Altogether 
these numbers support our conclusion that our raw data processing approach 
where multiple LCMS runs are combined before feature detection leads to a 
better detection of low abundant metabolites. With the joined analysis of 100 
LCMS samples we achieve up to a ten times increased feature detection rate. 
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A substantial amount of these features have very low mean intensity values 
below 1000 and even below 100 ion counts. 
 
Figure 2.7: Comparison of the dynamic range of metabolome intensities. Monoisotopic masses were 
annotated to the human metabolome database and peak intensities of the metabolites are shown for the 
HILIC (a) or RP dataset (b). Metabolites which were found with all algorithms are shown in gray. 
Metabolites identified by the matchedFilter, centWave or both of these algorithms are blue. Metabolites 
only annotated after processing with cosmiq are shown in red. 
 
2.5.4 Computation time 
Especially the feature detection steps using continuous wavelet 
transformation require much computation time in cosmiq. However, since the 
peak detection is performed on the combined data of all LCMS runs, this step 
is only computed once for all LCMS samples. As a result, the average 
computing time for each LCMS run decreases if multiple samples are 
included to the analysis (Figure 2.7). Since the amount of detected features 
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varied for each algorithm, we considered the computation time as a function 
of the feature number. For only two LCMS runs the computation time of 
cosmiq is almost one order of magnitude slower compared to the centWave 
algorithm, which also outperformed the matchedFilter. However for 50 or 
more LCMS runs, cosmiq performs equally fast. The runtime was calculated 
wall-clock timewise on a Intel Core i7 2.6 GHz processor with 16 GB RAM 
and Mac OSX 10.9 as the operating system. 
 
Figure 2.8: Computation time of the three peak detection algorithms centWave, matchedFilter and 
cosmiq. The total runtime of each processing step was averaged across each sample and normalized to 
the total number of detected peaks.  
 
2.6 Conclusion 
We present a novel approach for the processing of raw LCMS data with a 
focus on metabolomics or lipidomics applications. It is based on the idea that 
an overlay of multiple raw LCMS runs increases ion statistics and therefore 
the SNR. We integrated our workflow into an R package cosmiq, which can 
be well integrated with the popular software xcms. For a joined analysis of 
multiple LCMS runs, we demonstrate detection of up to ten times more 
features with a higher evectiveness compared to classical processing 
approaches. Therefore we recommend this approach especially for LCMS 
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based metabolomics applications where a large amount of samples have to be 
analysed.  
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3.1 Abstract 
Reprogramming of metabolism has been considered as hallmark of many 
different cancer types. High throughput technologies such as metabolomics 
are therefore invaluable to identify novel metabolic pathways or characterize 
existing pathways in established cancer models where metabolism is less 
investigated. Our current knowledge on cancer metabolism mainly originates 
from studies on cell lines or cancer biopsies whereas premalignant lesions are 
less understood in terms of metabolic reprogramming. In this study we 
provide an insight into metabolic alterations of neoplastic colorectal lesions 
and cancer by a combined analysis of the metabolome, lipidome and 
transcriptome of human biopsies. We show that enzymes and metabolites 
involved in glycolysis, nucleotide, serine, glutamine and proline metabolism 
are similarly deregulated in adenoma and cancer, suggesting that 
reprogramming of these pathways is an early event in colorectal 
tumorigenesis. These early metabolic changes might be mediated by the 
transcription factor MYC, because the expression of MYC-controlled genes 
and genes involved in these metabolic pathways are closely correlated. We 
further identify cancer specific expression of solute carrier genes (SLC) which 
are important for the intake of glucose and neutral amino acids, while 
transporter for cationic amino acids are upregulated in both lesions. The 
exclusive overexpression of some transporter genes in cancer and not in 
adenoma might explain our observation that some metabolites are only 
increased in cancer. Lipidome analysis revealed that many lipids with very 
long chained, polyunsaturated fatty acids are increased while low chained, 
saturated fatty acids are decreased in adenomas and cancer. The upregulation 
of genes involved in fatty acid synthesis, elongation and desaturation in these 
tissue support a scenario where these lipid classes are synthesized de novo. 
3.2 Introduction 
The study of metabolism in cancer research has gained much attention during 
the last years. Recently, the altered metabolic phenotype of cancer cells was 
added to the list of prominent hallmarks of cancer (Hanahan and Weinberg, 
2011). One of the well-known discoveries in this field is an increased aerobic 
production of lactic acid in cancerous versus normal tissue and was first 
described anno 1926 by Otto Warburg (Warburg, 1926). During the last 
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decade of research it became evident that cancer metabolism is linked to 
genetic alterations of molecular signalling pathways. For example, alterations 
in core metabolism were shown to be associated with activated oncogenes 
and mutant tumor suppressor genes (Vander Heiden et al., 2009). The 
transcription factor MYC has been shown to be responsible for the 
reprogramming of a broad range of different metabolic reactions (Li and 
Simon, 2013). Nowadays, a diverse spectrum of metabolic pathways beyond 
aerobic glycolysis are known to be characteristic for cancer cells. Among these 
pathways are several biosynthetic reactions of lipids, nucleotides, serine or 
proline (Benjamin et al., 2012; Liu et al., 2012). In addition to an increased 
demand for glucose, cancer cells also rely on glutamine as an important fuel 
for proliferation (Wise et al., 2008). In many cases where altered cancer 
metabolism was reported, the metabolic effect was identified as a growth 
advantage in order to allow cancer cells a rapid proliferation (Nomura et al., 
2010; Possemato et al., 2011; Son et al., 2013). However, inactivation of the 
APC gene and subsequent overexpression of the MYC gene was described as 
a key event of colorectal tumorigenesis and therefore MYC is already 
upregulated in pre-cancerous lesions (Sansom et al., 2007). Based on this 
premise, we hypothesized whether altered metabolism might not be only 
cancer-specific but already characteristic for early non-cancerous neoplastic 
lesions. In this study we therefore aimed to characterize metabolic alterations 
in benign colorectal adenomas and cancer by investigating the metabolome 
(metabolites and lipids) and transcriptome of human colorectal tissue. The 
metabolome is the ultimate biochemical output of the genome, transcriptome 
and proteome (Patti et al., 2012). A combined analysis of metabolomics data 
with other omics data can therefore improve our understanding of biological 
processes, such as metabolic adaptions to environmental changes (Kresnowati 
et al., 2006). Application of clustering and multivariate methods to 
transcriptomics and metabolomics data was employed to identify condition 
dependent links between specific genes and metabolites in microorganisms 
(Jozefczuk et al., 2010). These strategies might be also successful to better 
understand human malignancies such as colorectal cancer, and especially 
cancer metabolism. Metabolomics alone was already successfully applied to 
colorectal biopsies in order to identify metabolite alterations between cancer 
and normal mucosa (Denkert et al., 2008; Chan et al., 2009; Hirayama et al., 
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2009; Ong et al., 2010). These studies already highlighted deregulated 
metabolites involved in glycolysis, pentose phosphate pathway and amino 
acid and nucleotide metabolisms. With the hereby-presented study we want 
to provide a better insight into early metabolome changes in colorectal cancer 
development, notably in the pre-cancerous adenomas. In addition, we aim to 
identify the enzymatic reactions that are behind the metabolic 
reprogramming by integrating metabolomics and transcriptomics data. 
3.3 Materials and Methods 
3.3.1 Ethics approval 
The study was approved by the local ethics commission of the Kanton Zürich 
and written informed consent was obtained from each participating patient.  
3.3.2 Collection of biopsies 
Tissue biopsies of colorectal neoplasms and adjacent normal mucosa were 
collected during routine colonoscopy procedures. In order to avoid sampling 
of non-tumourous tissue, only a small sample (3-5 mg) from the tip of the 
tumor was taken. Only polyps with at least 10 mm diameter were considered 
to ensure that the sampling procedure would not interfere with the 
histological examinations. Lesions of the classes polypoid and non-polypoid 
were included to the study, according to the Paris classification system 
(Participants in the Paris Workshop, 2003). For the collection of normal 
mucosa, a small biopsy was taken from the healthy mucosa of the same colon 
segment with at least 2 cm space to the site of the lesion. The biopsy was 
immediately frozen in liquid nitrogen after removal and stored at -80° C until 
further usage.  
3.3.3 Metabolome and lipidome extraction and analysis 
The fresh weight of each frozen biopsy was determined and extraction 
solvent was added at a ratio of 100 µl per 3 mg biopsy. The extraction solvent 
consisted of 98% methanol, 1% metabolite internal standard solution and 1% 
lipid internal standard solution (See table A-1). Immediately after solvent 
addition the tissue was mechanically lysed in a glass homogenizer (Dounce 
homogenizer) on ice. The homogenate was centrifuged for 5 minutes at 4000 g 
and the clear methanol extract was removed for further analysis. For the 
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lipidomics and metabolomics analysis, we employed two capLCMS methods 
using self-packed capillary columns. For the metabolome analysis we used a 
HILIC method at basic conditions (pH9) and for the lipidome analyses we 
used a reversed phase (RP) method. For a detailed description of the methods 
we refer to table 1.1 in chapter 1.4.3. For the lipidome analyses we diluted the 
methanol extracts five times with buffer A of the RP method and transferred 
them to the autosampler vials for LCMS analysis. For metabolome analyses 
we dried the methanol extract using a vacuum concentrator (speedvac) and 
re-dissolved the dried metabolites in ultrapure water. This aqueous solution 
was diluted five times with the injection solvent mixture consisting of 50 mM 
ammonium acetate, 90% acetonitrile, 9% methanol and 1% ultrapure water 
adjusted to pH 9 with concentrated ammonia solution. Before LCMS analysis, 
the processed samples were centrifuged for 2 minutes at 4000 g to remove 
residual precipitates. MS analysis was performed on a waters Synapt G2 
HDMS mass spectrometer using positive (RP) or negative (HILIC) mode 
electrospray ionization (ESI+ or ESI-) at a scan rate of 0.3 scans per seconds 
(3Hz) in MSE mode (all ion fragmentation mode). Detailed MS tune settings 
were as described in section 1.3.3. 
3.3.4 LCMS data processing 
Continuum LCMS data were first centroided and then converted to vendor 
independent netCDF format using Waters MassLynx 4.1 and the integrated 
DataBridge software. The netCDF centroid data were then processed using 
the R package cosmiq, which was described in chapter 2. The following 
tuning parameters for the processing with cosmiq were used: Signal-to-noise 
ratio (SNR) of mass peak detection was set to 3, SNR for chromatographic 
detection to 20 and m/z bin size was set to 0.003 Da. The resulting peak table 
was first normalized by means of dividing the intensity values of each sample 
by the median intensity of selected internal standards (See appendix table A-
1). As a second step, each intensity value was log(2) transformed. The 
normalized data table was then matched to a library of metabolite standards 
with known retention time by mass and retention using a retention time 
cutoff of 20 seconds and a mass cutoff of 0.01 Da. For a list of these standards 
we refer to chapter 1, Table 1.3. For the annotation of unknown metabolites 
we compared the accurate mass against either the KEGG (Ogata et al., 1999) 
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or the HMDB database (Wishart et al., 2013). For the HILIC dataset we 
searched for possible hits assuming a [M-H]- ion. For the RP dataset we 
assumed [M+H]+ or [M+NH4]+ as possible adducts. In both cases we 
annotated database hits within a mass accuracy tolerance of 0.01 Da. 
3.3.5 Transcriptome data 
Transcriptomic data based on Affymetrix Exon 1.0 microarrays from our past 
studies were included in this work (Cattaneo et al., 2011; Maglietta et al., 
2012). Both studies contain data from colorectal biopsies of different tumor 
stages. We included the datasets of polypoid adenomas (n = 17), cancers (n = 
17), and adjacent normal mucosa (n = 34). Clinical and histological details of 
these cases are reported in the two references mentioned above. Both datasets 
are publicly available in the ArrayExpress database under the accession 
numbers E-GEOD-21962 and E-MTAB-829 (www.ebi.ac.uk/arrayexpress). 
The raw chip data were parsed using the most recent probeset information 
(Entrez gene ID, version 18) of the brainarray database (Dai et al., 2005), 
yielding a total number of 24681 probesets. Log(2) expression values were 
obtained using the robust multiple-chip analysis (RMA) algorithm (Irizarry, 
2003) and data was quantile normalized. 
3.3.6 Data analysis: statistics 
Large experimental datasets typically contain much more variables than 
observations and multivariate methods such as principal components analysis 
(PCA) are therefore not ideal to treat such data. Culhane et al. (2002) 
developed a classification method, which builds on ordination techniques 
such as PCA but circumvents the problem of having excess variables by 
ordinating the data based on predefined groups. This so called between 
group analysis (BGA) projects the data on N – 1 eigenvectors, where N is the 
total number of defined groups and each eigenvector distinguishes between 
two of these groups. The BGA function is available as part of the R package 
made4 (Culhane et al., 2005). Made4 was developed for the multivariate 
analysis of microarray data and mainly builds on the data ordination 
functions of another R package, ade4 (Thioulouse et al., 1997). We performed 
BGA in order to investigate the reflection of clinical phenotypes such as 
tumor stage or tumor size on the level of the three different omics datasets 
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(metabolomics, lipidomics, transcriptomics). Additionally we used BGA to 
classify genes, lipids and metabolites according to their expression level 
within these clinical phenotypes. The quantitative information for each 
variable (i.e. genes, metabolites and lipids) is transformed into the ordinated 
space such that a narrow angle between an ordinated variable and a certain 
group implies a good correlation between variable and group. Our 
classification approach therefore was to assign each variable to a group by 
selecting the closest angle between all group center coordinates and variable 
coordinates. The length of the ordination vector implies the contribution to 
each group, i.e. how significant each variable is altered within the group. In 
order to filter only for significant genes, metabolites or lipids, we applied a 
simple permutation test: The BGA was repeated 100 times with either of the 
three omics data matrices where each time the group label was randomly 
permuted. From the obtained random variable ordinations we calculated the 
euclidean distance between origin and the position at the first two 
discriminating axes. From this vector length distribution we chose the 99% 
percentile as a threshold for the ordinations in the non-permuted dataset. 
Each gene, lipid or metabolite with a length above this 99% percentile were 
considered as significant (See Appendix Figure A-6).  
3.3.7 Data analysis: Biological interpretation 
For the biological interpretation of the data we chose different approaches. 
First we performed a combined pathway over representation analysis of the 
metabolome and transcriptome data in order to investigate impacts in 
metabolic pathways. This analysis was done by parsing a list of annotated 
metabolites and genes to the webserver tool IMPaLA (Kamburov et al., 2011). 
The resulting list of pathways including enrichment analysis scores was 
exported and filtered for KEGG metabolic pathways only. For a more detailed 
investigation of single pathways we created networks based on KEGG 
pathway maps (Ogata et al., 1999). We obtained KGML files for each pathway 
from the KEGG homepage (www.genome.jp/kegg/pathway.html) and 
generated networks using cytoscape (Shannon et al., 2003). Each metabolite 
was represented as node and for each enzymatic reaction with one or more 
annotated human genes an edge was created between the nodes. 
Transcriptomics data were mapped on each edge and metabolomics data on 
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each node using color codes which represent the grouping from the BGA 
analysis. For some reactions there are multiple genes annotated, for example 
the five isoforms of the enzyme lactate dehydrogenase (LDHC, LDHB, 
LDHA, LDHAL6A, LDHAL6B). Metabolic pathways in the KEGG annotation 
however cannot distinguish between such isoforms. Our custom metabolic 
network maps have the advantage that each gene is individually displayed, 
which is important for cases where gene isoforms show a different expression 
pattern. For the analysis of solute carrier transporters (SLC), we annotated 
metabolite substrates based on the bioparadigms database, a web resource for 
existing knowledge about SLC genes and classes (www.bioparadigms.org) 
(Hediger et al., 2013). 
3.4 Results and Discussion 
3.4.1 Group classification reveals alterations in the metabolome, lipidome 
and transcriptome of different colorectal cancer progression stages 
The raw data processing yielded a total number of 24681 annotated gene 
transcripts, 23912 and 45714 non-annotated mass/retention time features for 
the metabolomics or lipidomics dataset, respectively. The metabolomics and 
lipidomics data in this work was obtained from a total of 49 paired colorectal 
lesions and normal mucosa biopsies (total, 98 tissue samples) from 39 patients 
(Table 3.1). The aim of this study was to interpret metabolic changes by 
integrating the molecular changes observed in all three omics datasets. Since 
the transcriptomics study was performed with a completely different patient 
cohort than in this study, we aimed to integrate the data according to clinical 
paramaters. Among the clinical factors that were annotated in both studies 
are lesion diameter, patient age, tissue type, degree of dysplasia, microscopic 
appearance or Paris classification (See Table 3.1 and tables of references 
(Cattaneo et al., 2011; Maglietta et al., 2012)). A BGA was calculated on the 
metabolomics dataset using different clinical parameters as grouping factors 
(Figure A-1). Based on this analysis, the grouping factor “tissue type” 
revealed the highest number of statistically altered metabolites between the 
groups (Figure A-1 c). Other factors, such as lesion diameter, patient age, 
Paris classification or degree of dysplasia (Appendix Figure A-1 b,f,d 
respectively) showed separation of the group clusters but only a low number 
of significant metabolite features, according to a 99% confidence threshold 
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from randomly permuted data (See materials and methods). The finding that 
tissue type was the most dominant discriminating factor to explain variation 
in the metabolome supported our observations from previous studies on the 
transcriptome, where the highest degree of gene expression variation was 
explained between normal mucosa, polypoid or non-polypoid lesions, or 
cancer (Sabates Bellver et al., 2007; Cattaneo et al., 2011). Motivated by this 
result we decided to apply BGA analysis on all omics data using the tissue 
types normal mucosa (NM), polyps (P) and cancer (CA) as grouping factors. 
The result of the BGA is shown in Figure 3.1 for metabolomics (Fig. 3.1 a), 
lipidomics (Fig 3.1 b) and transcriptomics (Fig 3.1 c) data. In every case, the 
first ordination axis separated between the groups NM and the two lesion 
types. For the metabolomics data the amount of explained variance was 77.7% 
for the first axis, indicating that the largest amount of metabolome changes 
account for the difference between normal mucosa and lesion. The second 
axis separated the two lesion types P and CA. For the transcriptomics dataset 
there was a clear separation of the three groups, whereas in the metabolomics 
and lipidomics dataset the NM and P group are overlapping. Interestingly, 
the CA cluster is further apart from the NM cluster on axis 1 in all datasets, 
indicating that common alterations in both lesion types are more discinct in 
the cancer tissue. For the analysis of metabolomics and other high throughput 
data it is important to validate classification methods, especially if supervised 
classification methods like BGA are used (Kjeldahl and Bro, 2010). In order to 
identify significant alterations in each of the omics data, we applied a 
permutation test (See material and methods). As the length of the vector in 
the n-dimensional ordination space implies its contribution to a certain group 
(Culhane et al., 2002), the coordinates of the first two axes were transformed 
to euclidean coordinates. All variables with a vector length above a 99% 
confidence threshold from the permutation test were considered as 
significant. This threshold is illustrated as red circle in Figure 3.1 in the right 
panel. As expected from the better separation of the groups NM, P and CA in 
the transcriptomics data, the amount of significantly differentially expressed 
genes is higher (36.6%) compared to altered metabolites (23.7%) or lipids 
(11.3%). To further investigate these lipid, metabolite and gene expression 
alterations, we classified each variable based on the three groups NM, P and 
CA (Figure 3.2). In the transformed ordination space, the variables which are 
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closely correlated to a certain group, lie in the same direction (Culhane et al., 
2002). Conversely, negatively correlated variables and groups lie in the 
opposite direction. We therefore assigned each variable to the group center 
with the closest angle (See Figure 3.2 left panel). In total we assigned all 
transcripts, metabolites and lipids according to six classes: Up- or 
downregulated in both CA and P (PCA up, PCA down, blue color), up- or 
downregulated in CA (CA up, CA down, red color) and up- or 
downregulated in P (P up, P down, yellow color). The resulting gene 
expression clusters are illustrated on the right panel of Figure 3.2 as relative 
mean intensity values for each class. Figure A-2 illustrates example genes 
from each classification cluster of the transcriptomics data. The class with the 
highest amount of the genes, metabolites and lipids was PCA up or PCA 
down (45, 55 and 51.7% respectively), indicating that a major part of the 
metabolic alterations is common to cancer and adenoma.  
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Table 3.1: Clinical parameters of patients involved in the metabolomics and lipidomics study. Lesions 
from a total of 39 patients were collected. na = no data available. 
 
Patient Age Sex
Colon 
segment  
involve
d
Maximum 
lesion 
diameter 
(mm)
Paris 
classifica
tion # 
Microscopic 
appearance
Highest 
degree of 
dysplasia in 
the lesion ▪ 
No. of  
lesions at 
study 
colonoscopy
No. of 
previously  
excised 
lesions ‡
1 65 M C 10 Iia-IIb TVA HGD 3 0
2 na na na na na na na na na
3 61 M A 10 Is TA LGD 3 0
4a 57 M A 40 Is TA LGD 5 2
4b D 30 Ip TVA CA
4c S 40 Ip TVA CA
5 49 M S 30 Is TA LGD 7 0
6a 55 M A 12 Ip TA LGD 3 0
6b D 10 Ip SA na
6c S 25 Ip TVA HGD
7 67 M S 10 IIa TVA HGD 4 0
8 76 F C 18 Iib-IIc TVA HGD 1 0
9 53 M LF 30 Ip TA HGD 1 0
10 61 M C 25 Is TVA LGD 0 0
11 54 M D 10 Ip na na 2 1
12 43 M S 26 Ip TA HGD 1 0
13 71 M HF 40 Is CA na 6 0
14 67 M T 12 Is TVA HGD 2 0
15 57 M S 23 Ip TVA Tis 4 1
16a 69 M S 20 Ip TVA HGD 6 0
16b S 20 Ip TVA HGD
17 57 M S 20 Ip TA HGD 1 0
18a 74 M HF 15 IIa TA HGD na na
18b S 40 Is TVA HGD
18c S 30 Is TVA HGD
19 56 M S 27 Is TA HGD 1 0
20 na na na na na na na na na
21 53 M S 10 Is TA HGD 3 0
22 55 M C 40 Iia-IIb TVA LGD 1 0
23a 73 M C 25 Is TA LGD 4 0
23b A 30 Ip TA LGD
24 63 M T 8 IIa TA LGD 4 0
25 75 M R 12 Is TVA LGD 0 6
26 na na na na na na na na na
27 49 M S 15 IIa na na 1 0
28 72 M S 20 Ip TVA LGD 2 0
29 44 F S 10 Is na na 3 0
30 73 M HF 20 Is TVA HGD 4 3
31 74 M D 15 Is TVA LGD 6 3
32 54 F R 25 Is SA HGD 3 0
33 48 F S 40 Is TA CA 1 0
34 na na na na na na na na na
35a 77 F C 30 IIa TVA HGD 5 0
35b C 30 IIa TVA HGD
35c A 30 IIa na na
36 na na na na na na na na na
37 75 F na 40 na CA CA na na
38 62 M na 40 na CA CA na na
39 58 M S 25 Ip TA HGD 0 0
Abbreviations: M, male; F, female; C, caecum; A, ascending colon; HF, hepatic flexure; T, transversum;  D, descending colon; S, sigma; R, 
rectum;  TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; MVSP, microvescicular serrated polyp; SA, serrated 
adenoma; SSA, sessile serrated adenoma; LGD, low-grade dysplasia; HGD, high-grade dysplasia.
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic Classification.  The Paris Endoscopic 
Classification of Superficial Neoplastic Lesions. Gastrointest Endosc 2003;58(suppl.):S3-S27
▪ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumors of the digestive system, editorial and 
consensus conference in Lyon, France, November 6-9, 1999.IARC
‡ Total no. adenomas detected and excised during previous colonoscopies.
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Figure 3.1: Between group analysis (BGA) of metabolomics (a), lipidomics (b) and transcriptomics data 
(c). The BGA was calculated using the group factor “tissue type” with the levels: normal mucosa (NM), 
polyp (P) and cancer (CA). The left panel shows the score plot (samples) of the first two BGA axes. The 
group center for each group is indicated by a square and a 50% confidence ellipse is shown for each 
group. The right panels shows the loadings plot (variables). The red ellipse in the loadings plot 
illustrates the 99% percentile of randomly generated loadings (See material and methods for details). 
The amount of variance for each BGA axis is given as percent of total variance. 
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Figure 3.2: Classification of the metabolome (a), lipidome (b) and transcriptome (c) according to the 
between group analysis (BGA) and the grouping information for normal mucosa (NM), polyp (P) and 
cancer (CA). The left panel shows the loadings plot as in Figure 3.1, but highlights the loadings 
according to the class they were assigned to: Blue: deregulated in polyps and cancer (PCA up/PCA 
down), yellow: Deregulated only in polyps (P up/ P down) and red: deregulated in cancer only (CA 
up/ CA down). Grey: Loadings inside the confidence ellipse. Up/down indicates whether transcripts, 
metabolites or lipids are increased or decreased, respectively. The right panel shows relative mean 
intensity values for each metabolite with significant contribution.  
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3.4.2 Alteration of metabolic pathways  
A total of 187 annotated metabolites were significantly changed and classified 
according to the BGA analysis. For each of these metabolites we calculated 
log(2)-fold changes between their abundance in the lesion and normal mucosa 
(Figure 3.3). 77 were classified as altered in PCA (Fig. 3.3 a), 75 as altered in 
CA (Fig. 3.3 b) and 35 as altered in P (Fig 3.3 c). While half of the metabolites 
in the class PCA were increased in cancer and polyps and the other half 
decreased, most of the metabolites in the class CA were increased. 
Interestingly, for almost all metabolites in the class PCA the fold change was 
higher in cancer compared to adenomas. Also, most metabolites in the class 
CA show a similar alteration trend for the adenomas as in cancer. For 
example, decanoyl-CoA with a high fold change of 4.1 in cancer is also 
increased by a lower fold change of 1.4 in adenomas (Fig 3.3 b). The fold 
changes in the P class are generally lower compared to the classes PCA and 
CA. Also, the fold change difference between adenoma and cancer is in many 
cases quite low. Interestingly, some compounds in this class show completely 
different trends in fold change. For example, arachidonate is increased in 
adenomas, wheras it is decreased in cancer. Overall, most metabolite fold 
changes show a similar trend in adenomas and cancer, whereas the amount of 
fold change is considerably greater in cancer. Taken together, these results 
implicate a nearly overlapping alteration in metabolism for both adenoma 
and cancer. However it seems that the amount of variation is more advanced 
in cancer.  
Figure 3.3 (next page): Metabolite fold changes comparing cancer (CA) versus normal mucosa (NM) in red, or 
adenoma (P) versus normal mucosa (yellow). The metabolites were classified according to BGA analysis (See 
Figure 3.2): a) deregulated in adenoma and cancer, b) deregulated in cancer and c) deregulated in adenoma. 
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In order to interpret the metabolic changes in adenomas and cancer, we next 
performed a pathway overrepresentation analysis. Both transcriptomics and 
annotated metabolomics data were parsed to the web-based IMPaLA tool 
(Kamburov et al., 2011). For each of the BGA classes we retrieved a list of 
significantly altered metabolic pathways (Table 3.2). Interestingly, the 
analysis revealed some metabolic pathways to be common for polyps and 
cancer which are known to be involved in metabolic reprogramming of 
cancer (Nucleotide metabolism, Pentose phosphate metabolism, glycolysis, 
fatty acid biosynthesis) (DeBerardinis et al., 2008). In cancer, these pathways 
are together involved in an increased uptake of glucose in order to provide 
enough energy and carbon backbone structures for the production of biomass 
(DNA, RNA and lipids). The overrepresentation of these pathways in both 
cancer and polyps points to a metabolic alteration which is already present in 
early lesions and persist when the polyps progress to cancer. Other pathways 
such as arginine/proline metabolism or glycine/serine threonine seem to be 
differently altered in the polyps or in cancer. The results of the pathway 
analysis are together highlighted on a global metabolic pathway map (Figure 
3.4 for the transcriptomics data and Figure 3.5 for metabolomics data). 
Interestingly, in most of the pathways the predominating genes are in the 
PCA class whereas for the metabolites most are in the CA class. This 
observation indicates that most alterations in enzyme gene expression level 
may be shared by adenomas and cancer whereas many metabolites are only 
altered in cancer. The map in Figure 3.4 indicates that many alterations in 
enzyme gene expression are spread across many different kinds of metabolic 
pathways, whereas the metabolite changes are more dominating around 
central carbon, nucleotide and amino acid metabolism (Figure 3.5).  
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Table 3.2: Integrated pathway overrepresentation analysis of metabolomics and transcriptomics data 
using IMPaLA (Kamburov et al., 2011). Only KEGG pathways involved in metabolism and with p-joint 
value <= 0.05 were retrieved. P-values represent pathway significance according to hypergeometric 
distribution calculation (Cavill et al., 2011). 
 
KEGG Pathway Name #genes p  genes #metabolites p metabolites p  joint
Deregulated in polyps and cancer
Purine metabolism 66 5.44E-07 5 0.0303 1.65E-08
Pyrimidine metabolism 47 1.54E-07 2 3.61E-01 5.57E-08
Amino sugar and nucleotide sugar 
metabolism 11 0.464 9 7.76E-05 3.60E-05
Tryptophan metabolism 10 0.381 8 1.40E-04 5.34E-05
Inositol phosphate metabolism 19 0.0615 5 1.36E-03 8.34E-05
N-Glycan biosynthesis 23 0.000093 0 1 0.000093
Glycerophospholipid metabolism 21 0.442 6 0.000405 0.000179
Pyruvate metabolism 16 0.0101 3 0.0224 0.000226
Pentose phosphate pathway 12 0.0108 3 0.0263 0.000284
Fructose and mannose metabolism 10 0.255 5 0.00265 0.000674
Galactose metabolism 11 0.0481 3 0.0426 0.00205
Tyrosine metabolism 11 0.223 5 0.0144 0.00321
Glycolysis / Gluconeogenesis 18 0.185 3 0.0206 0.0038
Phenylalanine. tyrosine and tryptophan 
biosynthesis 4 0.00962 1 0.473 0.00455
Taurine and hypotaurine metabolism 1 0.917 3 0.00797 0.0073
Glycerolipid metabolism 19 0.0221 1 0.473 0.0104
Cysteine and methionine metabolism 14 0.0161 1 0.67 0.0108
Alanine. aspartate and glutamate 
metabolism 12 0.0335 1 0.372 0.0125
Vitamin B6 metabolism 3 0.125 2 0.124 0.0155
Sulfur metabolism 5 0.0477 1 0.43 0.0205
Fatty acid biosynthesis 4 0.0238 0 1 0.0238
Phenylalanine metabolism 8 0.0281 0 1 0.0281
Terpenoid backbone biosynthesis 4 0.71 3 0.0453 0.0321
Glutathione metabolism 16 0.0771 1 0.522 0.0402
Lysine degradation 9 0.78 3 0.0598 0.0467
Deregulated in polyps
Alanine. aspartate and glutamate 
metabolism 2 0.85 4 4.98E-05 4.23E-05
D-Arginine and D-ornithine metabolism 0 1 3 7.49E-05 7.49E-05
Arginine and proline metabolism 2 0.984 6 0.000117 0.000115
Tyrosine metabolism 5 0.363 5 0.000493 0.000179
Valine. leucine and isoleucine degradation 5 0.467 4 0.000426 0.000199
Purine metabolism 9 0.993 5 0.00119 0.00118
Propanoate metabolism 3 0.644 3 0.0038 0.00245
Glycosylphosphatidylinositol(GPI)-anchor 
biosynthesis 8 0.00246 0 1 0.00246
Pyrimidine metabolism 5 0.986 4 0.00259 0.00255
Glycosaminoglycan degradation 6 0.00918 0 1 0.00918
Mucin type O-Glycan biosynthesis 8 0.0104 0 1 0.0104
Linoleic acid metabolism 0 1 2 0.0253 0.0253
Glycine. serine and threonine metabolism 5 0.342 2 0.0752 0.0257
Amino sugar and nucleotide sugar 
metabolism 9 0.0443 1 0.585 0.0259
Vitamin B6 metabolism 2 0.117 1 0.25 0.0293
Primary bile acid biosynthesis 4 0.0862 1 0.345 0.0298
Butanoate metabolism 2 0.757 2 0.0511 0.0387
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Figure 3.4 (page 80): Representation of metabolic pathways according to the number of altered 
transcriptome. Each circle represents a KEGG metabolic pathway. Circle size represents relative amount 
of deregulated genes within each pathway. The colored pie graphs indicate the amount of altered genes 
within one of the three BGA classes: blue: deregulated in adenoma and cancer, yellow: deregulated in 
adenoma, red: deregulated in cancer. 
 
Figure 3.5 (page 81): Same as Figure 3.4 for the metabolomics data.    
KEGG Pathway Name #genes p  genes #metabolites p metabolites p  joint
Deregulated in Cancer
beta-Alanine metabolism 10 3.65E-03 5 0.000258 9.40E-07
Alanine. aspartate and glutamate 
metabolism 3 0.831 6 4.09E-06 3.40E-06
Pentose phosphate pathway 5 0.332 6 0.0000351 1.17E-05
Cyanoamino acid metabolism 1 0.641 7 2.08E-05 1.33E-05
Glycine. serine and threonine metabolism 2 0.973 7 0.0000416 0.0000405
D-Glutamine and D-glutamate metabolism 0 1 4 0.0000544 0.0000544
Amino sugar and nucleotide sugar 
metabolism 5 0.786 9 0.0000776 0.000061
Arginine and proline metabolism 8 0.522 8 0.00027 0.000141
Glycolysis / Gluconeogenesis 9 0.554 5 0.000258 0.000143
Propanoate metabolism 10 0.00801 3 0.0305 0.000245
Butanoate metabolism 8 0.0188 3 0.0426 0.000801
Fructose and mannose metabolism 6 0.366 5 0.00265 0.000968
Pentose and glucuronate interconversions 5 0.502 5 0.00265 0.00133
Starch and sucrose metabolism 7 0.656 5 0.00265 0.00174
Biosynthesis of unsaturated fatty acids 8 0.00456 1 0.65 0.00297
Glutathione metabolism 7 0.554 4 0.00557 0.00308
Cysteine and methionine metabolism 2 0.966 5 0.00431 0.00417
Fatty acid elongation 8 0.00856 1 0.503 0.0043
Nicotinate and nicotinamide metabolism 7 0.0768 3 0.0598 0.00459
Galactose metabolism 2 0.93 4 0.00732 0.0068
Pyrimidine metabolism 11 0.864 5 0.00806 0.00696
Pantothenate and CoA biosynthesis 5 0.0706 2 0.0992 0.007
Lysine degradation 11 0.062 2 0.226 0.014
Valine. leucine and isoleucine biosynthesis 1 0.254 2 0.0705 0.0179
Tryptophan metabolism 10 0.0383 2 0.468 0.018
Pyruvate metabolism 3 0.932 3 0.0224 0.0209
Glyoxylate and dicarboxylate metabolism 5 0.221 3 0.0983 0.0218
Glycerolipid metabolism 4 0.953 3 0.0243 0.0232
Synthesis and degradation of ketone bodies 4 0.0245 0 1 0.0245
Glycosphingolipid biosynthesis - globo series 5 0.0323 0 1 0.0323
Lipoic acid metabolism 1 0.356 1 0.109 0.0389
Metabolism of xenobiotics by cytochrome 
P450 13 0.202 4 0.2 0.0403
Drug metabolism - other enzymes 8 0.285 2 0.17 0.0486
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3.4.3 Alteration of central metabolism is an early hallmark of colorectal 
cancer development  
From the pathway overrepresentation analysis it became evident that central 
carbon metabolism, nucleotide metabolism and several amino acid 
metabolism pathways are altered based on differential expression of enzyme 
genes and metabolite changes. During the last years of research several 
metabolic alterations of cancer cells within these pathways were uncovered 
(DeBerardinis et al., 2008). Two main metabolic fuels, glucose and glutamine, 
support proliferating cells for energetic and biosynthesis processes. Beyond 
the well known Warburg effect, where glucose is converted to lactic acid, 
cancer cells utilize synthetic reactions for nucleotides, lipids, serine or proline 
(Benjamin et al., 2012; Li and Simon, 2013). We therefore investigated these 
metabolic pathways in more detail (Figure 3.6). Intriguingly, our gene 
expression data suggests that a major fraction of enzyme genes for these 
synthetic and energetically important reactions are upregulated in adenomas 
and cancer, i.e. all of these genes were classified as upregulated in PCA 
according to the BGA. We observe an increase in gene expression for GPI, 
PFKM, GAPDH or PGK1, indicating an increased glycolytic activity in 
adenomas and cancer. Other increased expressions for genes such as G6PD, 
PGD, TKT or PRPS2 suggest that reactions of the pentose phosphate pathway 
are induced to generate 5-phosphoribosyl diphosphate (PRPP), an important 
precursor for nucleotide synthesis. An increased generation of nucleotides is 
also indicated by the expression of UMPS, PPAT, CAD, DHODH and GART. 
These genes are responsible for the first steps of purine and pyrimidine 
synthesis, involving PRPP and glutamine as metabolite precursors. In 
addition to the genes responsible for these initial reactions, most of the 
enzymatic genes responsible for interconversion of different purine und 
pyrimidine nucleotides are overexpressed as well (See Appendix Figure A-3 
and A-4). Also important for the generation of purines is the incorporation of 
a glycine carbon during one-carbon metabolism reactions. Recent studies 
have shown that serine and subsequent glycine production is important for 
the rapid growth of cancer cells (Locasale et al., 2011; Possemato et al., 2011; 
Jain et al., 2012). Interestingly, these important genes for serine biosynthesis 
are overexpressed in our dataset for adenoma and cancer (PSAT1, PSPH, 
SHMT2). Another recent discovery in cancer metabolism is the synthesis of 
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proline from glutamine, which is believed to play an important role in redox 
balance (Liu et al., 2012; Phang et al., 2012). We found the relevant genes for 
these reactions to be overexpressed in our dataset (GLS2, ALDH4A1, PYCR1, 
PYCRL, PYRC2). Finally, another recent study report the KRAS mediated 
conversion of glutamine via aspartate and malate to pyruvate (Son et al., 
2013). Again, the responsible genes are overexpressed in adenomas and 
cancer (GOT2, MDH2, ME1). In summary, these data indicate that many of 
the known metabolic changes, which are mostly induced by an upregulation 
of relevant enzyme genes, are observable already in premalignant colorectal 
lesions. Consequently, the metabolic adaptation within these pathways might 
be already an early event of colorectal carcinogenesis and persists during the 
progression to cancer. Interestingly, we see also many changes in the 
metabolome within these pathways. For example proline, glutamine, 
glutamate, 5-phosphoribosylamine, phosphoserine and glycine are increased. 
This gives us further evidence to believe that the biosynthetic activity for 
these substances is increased in early colorectal lesions, i.e adenomas. 
Interestingly however, most of the metabolites associated with these 
pathways were increased only in cancer and not in adenomas. 
 
Figure 3.6: Metabolomic and transcriptomic changes of core metabolism in colorectal adenomas and 
cancer. Metabolites are represented as circles and enzymatic reactions are shown as arrows. Relevant 
genes for each enzymatic reaction are indicated on the arrows. Metabolic reactions were obtained from 
KEGG database (Ogata et al., 1999), the network was created using cytoscape (Barupal et al., 2012). 
Gene overexpression or metabolite increase is indicated in bold, gene downregulation or metabolite 
decrease is indicated in light print. Genes and metabolites are colored according to the BGA groups: 
blue: deregulation in adenoma and cancer, yellow: deregulation in adenoma, red: deregulation in 
cancer. Genes and metabolites without expression alteration or which could not be detected in the 
LCMS data are shown in grey.  
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3.4.4 Investigation of solute carrier transporters (SLC) and its substrates 
Increased metabolism of glucose and glutamine is accompanied by an 
increased uptake of these substances into cancer cells (Kroemer and 
Pouyssegur, 2008). For example, the need for glucose is maintained by an 
increased production of the glucose transporter GLUT-1, a cancer hallmark 
which is nowadays exploited as a standard tool in clinical cancer diagnostics 
(Som et al., 1980; Kunkel et al., 2003). Uptake of metabolites into cells is 
mainly mediated through the so called solute carrier (SLC) transporter class 
(Hediger et al., 2013). Until now there are 52 transporter classes with a total of 
395 genes described and maintained within the bioparadigms database 
(http://slc.bioparadigms.org). For many of these genes in the database there 
is a list of known transported subtances available. In order to further 
characterize the metabolic alterations of colorectal cancer and adenoma, we 
investigated the expression of SLC genes in our dataset (Figure 3.7). Of all the 
annotated 395 genes we could identify 376, from which 175 were classified 
according to the BGA analysis (93 deregulated in PCA, 58 in CA and 24 in P). 
Consistent with the expression of enzyme genes, most of the differentially 
expressed transporter genes are altered in adenoma and cancer, suggesting 
that a major part of metabolism is similar in adenomas and cancer. Of the 
upregulated genes within this class, many are involved in amino acid uptake, 
especially those of cationic nature (SLC7A11, SLC6A14, SLC7A1, SLC7A6, 
SLC25A15, Figure 3.7 a). The transporter gene SLC6A6 with the highest fold 
change in this class is coding for a taurine transport protein. Interestingly, 
taurine itself showed up as one of the most increased compounds in our 
metabolomics dataset, also in adenoma and cancer (See Figure 3.3 a). For the 
cancer specific expression of transporter genes we observe neutral amino acid 
transporter genes (SLC7A5, SLC3A2, SLC1A5) and hexose transporter genes 
(SLC2A3, SLC2A1) as top 5 overexpressed genes (Figure 3.7 b). SLC2A1 and 
SLC2A3 are better known as GLUT1 and GLUT3 and known for their role as 
glucose transporter in cancer (Szablewski, 2013). SLC7A5 (LAT1) and SLC1A5 
(ASCT2) are believed to work in a cooperative manner with the aim to import 
glutamine and other neutral amino acids (Fuchs and Bode, 2005). 
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Figure 3.7: Log(2) fold change of SLC transporter gene expression for cancer versus normal mucosa 
(red) and adenoma versus normal mucosa (yellow). The expression values are sorted according to the 
maximal fold change. The columns were selected after the BGA classification: a) deregulated in 
adenoma and cancer, b) deregulated in adenoma, c) deregulated in cancer. 
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3.4.5 Upregulation of the MYC gene and its downstream targets in 
colorectal cancer and adenomas  
Mutations in the APC gene and a subsequently increased expression of the 
MYC gene have been considered as key event in sporadic and hereditary 
initiation of colorectal tumors (Sansom et al., 2007). MYC itself is described as 
a transcription factor involved in the activation of multiple metabolic genes 
involved in glycolysis, glutamine, serine or proline metabolism (Li and 
Simon, 2013). Many of these genes are shown in this study to be upregulated 
in adenomas and cancer, resulting in an increase of metabolites within 
relevant metabolic pathways (Figure 3.6). We therefore hypothesized whether 
the activation of MYC in early stages of colorectal tumors is responsible for a 
metabolic reprogramming that persists during each stage of tumor 
progression. In order to test this hypothesis our idea was to investigate the 
expression of MYC and MYC-target genes in our dataset. We used a list of 
genes that were shown to be specific MYC targets independent of cell type 
(Table A-3) (Ji et al., 2011). 77 of these 98 genes were significantly deregulated 
in our transcriptomics dataset according to the BGA clustering. Of these, 
92.2% as well as the MYC gene itself were classified as upregulated in cancer 
and adenomas (Figure 3.8). These data together indicate that many enzyme 
genes which are equally upregulated in adenomas and cancer might be 
regulated by the MYC transcription factor.  
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Figure 3.8: Loadings plot of the between group analysis (BGA) based on transcriptomics data. This is 
the same representation as seen in Figure 3.2 c). Green circle indicates position of the MYC gene, black 
boxes indicate positions of MYC target genes (See Table A-3). 
3.4.6 Lipidomics profiling reveals a role for polyunsaturated, very long 
chained fatty acid synthesis in colorectal cancer development 
Several pathways involved in lipid metabolism were shown to be 
significantly altered in our overrepresentation analysis (See Table 3.2). 
Interestingly, among the few adenoma specific metabolite changes were two 
very long chain polyunsaturated fatty acids (VLC-PUFAs), arachidonic acid 
and eicosatrienoic acid. We therefore wanted to investigate the lipidome 
composition of colorectal adenomas and cancer in more detail. Compared to 
the metabolomics and transcriptomics dataset, the variance within the 
lipidomics data was high and the NM, P and CA group were not well 
separated in the BGA analysis (Figure 3.1). Especially the polyp and normal 
mucosa groups showed a clear overlap. Still, a total number of 252 lipids were 
−1 −0.5 0 0.5 1
−1
−0.8
−0.6
−0.4
−0.2
0
0.2
0.4
0.6
0.8
1
BGA Axis 1: 65.3%
B
G
A
 A
xi
s 
2:
 3
4.
7%
 88 
significantly altered according to the BGA analysis. The predominant lipid 
classes were triradylglycerols (TG), followed by glycerophophocholines (PC) 
and glycerophosphoserines (PS) (Figure 3.9).  
 
Figure 3.9: Distribution of deregulated lipids according to their lipidmaps classification (Fahy et al., 
2009). 
For each annotated lipid, we calculated the average carbon number (#C) and 
average double bond number (#n) of the attached fatty acyl residues (Figure 
3.10). Most strikingly, almost all TG lipids with fatty acyl residues greater 
than 18 #C were upregulated in adenoma and cancer. About half of these 
fatty acyls showed a #n higher than 2, suggesting that most of the 
upregulated TGs contain VLC-PUFAs. In contrast, all decreased TGs contain 
fatty acyl groups with maximal 18 #C and less than 2 #n. The same trend was 
observed for Diradylglycerols (DG) and Glycerophosphoglycerols (PG) where 
also VLC-PUFA containing lipids were increased, and lipids with smaller and 
more saturated fatty acyls were decreased. In other lipid classes we observed 
different trends. Glycerophosphoinositols (GPI) for example were only found 
to be downregulated. This was true for GPI containing VLC-PUFA but also 
for shorter fatty acyl chains with less double bonds. In the 
glycerophophocholine (PC) class VLC-PUFA containing lipids were 
decreased and PCs with very long chain saturated fatty acyls were increased. 
Interestingly, the amount of fold change between lesion and normal mucosa 
was higher in cancer for many of the VLC-PUFA containing lipids, especially 
in the DG and PG class.  
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Figure 3.10: Average number of fatty acyl carbon (#C) and number of double bonds (#n) for each 
annotated lipid. The log(2) fold change is displayed for adenoma versus normal mucosa (circle) and 
cancer versus normal mucosa (box). Only the most 6 abundant lipid classes (Figure 3.9) are shown. 
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3.4.7 Expression of enzymes involved in lipid metabolism 
The increase of different lipid classes with VLC-PUFA fatty acyl chains raised 
the question for an enzymatic mechanism which favours such long and 
unsatured fatty acyls in lipids. Some genes involved in fatty acid biosynthesis 
and fatty acid elongation were over represented in our pathway analysis. We 
therefore speculate that an increase in these pathways may lead to the 
phenotype with a high amount of VLC-PUFA in cancer and adenoma lipids. 
We had a detailed look at the genes involved in fatty acid metabolism 
pathway in KEGG, which includes fatty acid biosynthesis, elongation, 
desaturation and mitochondrial fatty acid metabolism. 36 of a total of 48 
genes in this pathway were unambiguously classified according to the BGA 
analysis (See Figure 3.2). A detailed view of all reaction steps including the 
mapping of deregulated genes within the different BGA classes can be seen in 
Appendix Figure A-5. We summarized these steps according to the cellular 
location of the reactions (mitochondrial, cytoplasmic, endoplasmic reticulum 
ER) in Figure 3.11. Among the increased genes in adenoma and cancer are 
FASN and ACACA. These genes are important for the initiation of fatty acid 
synthesis in the cytoplasm and the generation of palmitate. Interestingly, 
most of the genes involved in fatty acid elongation or fatty acid desaturation 
are increased in cancer. Especially FADS1, FADS2 and SCD5 show exclusive 
upregulation in cancer whereas SCD is also increased in adenoma. Finally, 
almost all mitochondrial enzyme genes are downregulated. Many of these 
mitochondrial genes play a role in fatty acid oxidation (e.g. ACOX1, CPT2, 
CPT1A). Again, some of these genes are uniquely downregulated in cancer 
(ACADM, ACADVL, ACADSB), wheres others are deregulated in both 
adenoma in cancer. Together, these results imply that adenoma and 
predominantly cancer cells increase their de-novo biosynthesis, elongation 
and desaturation of fatty acids while genes involved in mitochondrial fatty 
acid metabolism are downregulated. As a complement to the lipidomics 
analysis, these gene alterations might explain the increase of VLC-PUFA 
containing lipids in the colorectal lesions, especially in cancer tissue. 
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Figure 3.11: Deregulation of genes involved in fatty acid metabolism. Each gene is represented as box 
and is connected via an edge to its biological function displayed in grey. Gene overexpression is 
indicated in bold, downregulation in light print. Red: deregulated in cancer, blue: deregulated in cancer 
and adenoma, yellow: deregulated in adenoma. 
 
 
3.5 Conclusion 
In this study we investigated the metabolome and lipidome alterations of 49 
colorectal lesions compared to adjacent mucosa from a total of 39 patients. For 
better interpretation of the metabolomics and lipidomics data we included 
transcriptomics data from our previous studies (Cattaneo et al., 2011; 
Maglietta et al., 2012). We applied a supervised multivariate method 
(between-group analysis, (Culhane et al., 2002)) to classify metabolites, lipids 
and transcripts according to their abundances in three tissue types: normal 
mucosa, adenoma and cancer. According to this classification most of the 
transcriptome, metabolome and lipidome alterations were similar in both 
lesion types, suggesting that most metabolic changes in colorectal cancer and 
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adenoma tissue are identical. We then investigated metabolic changes using 
pathway overrepresentation analysis and observed that central metabolic 
pathways such as glycolysis, nucleotide synthesis, proline synthesis, serine 
synthesis and fatty acid synthesis were affected at the metabolome and 
transcriptome level. Interestingly, most of the enzyme genes within these 
pathways are upregulated in both adenomas and cancer, suggesting that 
reprogramming of central metabolism is an early event in colorectal 
carcinogenesis. Previous studies in cancer metabolism have already shown 
that the MYC gene plays a central role in controlling central carbon 
metabolism in cancer (Li and Simon, 2013). Since upregulation of the MYC 
gene is one of the first events in colorectal tumor evolution (Sansom et al., 
2007), we speculated about the role of MYC as one mediator of these 
metabolic changes. In support of this theory, we showed that the expression 
of MYC and 92.2% of a selection of MYC controlled genes (Ji et al., 2011) 
correlate with the expression of central carbon metabolism genes. 
Interestingly, many metabolite alterations were more dramatic in cancer than 
in adenomas such as for glutamate, glutamine or glucose. In addition, we 
observed solute carrier genes (SLC), which were overexpressed specifically in 
cancer. Among these SLC genes were transporter for glucose, glutamine and 
glutamate. Considering all these facts, we speculate that a specific 
overexpression of these transporters in cancer causes an increased intake of 
these metabolites compared to adenomas, which together might lead to a 
more aggressive proliferation. Two of these transporters, GLUT1 and LAT1, 
were already shown as predictive markers of poor response in clinical 
colorectal and rectal cancer therapy (Ebara et al., 2010; Shim et al., 2013). In 
addition to central carbon metabolism, fatty acid and lipid metabolism was 
altered on the transcriptome and metabolome level. Among the few adenoma 
specific metabolite alterations were two VLC-PUFA classes, arachidonic acid 
and eicosatrienoic acid. Lipidomics analysis revealed that adenomas and 
cancer showed an increase of lipids with VLC-PUFA fatty acyls while lipids 
with low chain, saturated fatty acyls were decreased. Along with these 
observations we found an increased gene expression for the biosynthesis and 
elongation of fatty acids, especially in cancer. Together, these results implicate 
de-novo synthesis and accumulation of VLC-PUFAs in colorectal adenomas 
and cancer. This synthesis capacity may play an important role in COX-2 
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related arachidonic acid metabolism of colorectal cancer (Oshima et al., 1996; 
Castellone, 2005). 
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Conclusions and perspectives 
In the first two parts of this thesis we report the development of novel 
analytical strategies for untargeted metabolomics with the aim to improve 
overall sensitivity and coverage of different metabolite classes. We 
demonstrate two complementary capillary LCMS methods (capLCMS), one 
for the analysis of polar metabolites and one for unpolar metabolites and 
lipids. With both methods we achieve very good sensitivity in the femtomolar 
range and a broad coverage of the metabolome and lipidome from a low 
amount of colorectal tissue sample. Together, these methods enable us to 
cover about 50% of the masses annotated in the KEGG database and about 
700 lipids in the lipidmaps database by accurate mass. With such an 
untargeted metabolomics approach we have the possibility to explore 
metabolic changes of multiple metabolic pathways. However, the 
identification of unknown metabolites in such an untargeted approach was 
mainly restricted to the annotation of accurate mass information to a 
metabolite database with known masses. The presence of isomeric 
compounds for example does not allow to unambiguously annotate each 
metabolite by one single mass. If the chromatographic dimension does allow 
for separation of isomers then additional information is needed to distinguish 
between them. In our case we demonstrate the separation of three hexose-
phosphate classes using HILIC chromatography. For these compounds we 
could annotate the metabolite identity by retention time from reference 
standards. If no such standards can be used, annotation of each isomer by 
accurate mass alone is not possible. In order to improve the annotation of 
metabolites in an untargeted metabolomics experiment, mass fragment data 
can be included. This strategy not only may help to distinguish between 
isomers but also may confirm the identity of the metabolites which were 
annotated by accurate mass. Traditionally, data dependent acquisition (DDA) 
is used in exploratory mass spectrometry, especially in the area of proteomics 
(Mann et al., 2001). In this acquisition mode, mass spectrometers first generate 
a full scan mass spectrum, from which the top ten most intense ions are 
selected for subsequent MS/MS experiments. The selected ions, termed 
precursor ions, generate mass fragments which aid the identification of each 
precursor. Main disadvantages of this method are that only these high 
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abundant ions are considered while low abundant ions are ignored. Also, the 
duty cycle of DDA needs to be considered and consequently the 
chromatographic separation should not be too fast. In untargeted 
metabolomics however, mass spectra are typically recorded in MS full scan 
mode and further MS/MS experiments are performed to confirm the identity 
of a small list of interesting masses, either together with a pure standard or by 
parsing the MS/MS spectra to a database (Patti et al., 2012). This process is 
very time consuming and needs much additional manual work. An 
alternative to DDA is data independent acquisition (DIA). In this acquisition 
mode, two parallel alternating scans are recorded either with low or high 
collision energy (Plumb et al., 2006). In variation first implemented by Waters 
and termed MSE (MS with “energy”), DIA provides fragmentation of all ions 
acquired during a full scan MS and provides the potential to annotate 
fragment information for all ions. Typically, the duty cycle for these 
acquisition modes results in 50% low energy and 50% high collision energy 
time which makes this technique suitable for fast analysis with rapidly eluting 
chromatographic peaks. Especially in untargeted lipidomics applications, 
where many different isomeric compounds are expected, DIA was applied 
with good success (Castro-Perez et al., 2010; Hummel et al., 2011; Knittelfelder 
et al., 2014). Our analytical methods which were described in this thesis are 
designed to provide a fast and sensitive metabolome and lipidome analysis. 
The additional use of DIA techniques would further improve the 
interpretation and annotation of metabolites. For example, with the exact 
mass information we were able to annotate most lipids with a total amount of 
carbon and double bond in their fatty acyl chains. Therefore, the 
interpretation allows only for an average length and saturation status of the 
fatty acyl chains. Using DIA information it would be possible to identify the 
fatty acyl chain length as well as saturation status for each individual lipid 
(Castro-Perez et al., 2010). Since untargeted metabolomics strategies involve 
the detection of thousands of unknown masses, there is also a need for an 
automatic and comprehensive interpretation of such fragmentation data. In 
DDA, the precursor ions are isolated from disturbing background and the 
resulting fragments can be directly referred back to each precursor. In 
contrast, precursor-fragment assignment in DIA is challenging and until 
today there is no widely adopted software available for the automatic 
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processing of DIA data in untargeted metabolomics. Recently, a strategy 
using open source software tools was described to annotate precursor-
fragment relationships (Broeckling et al., 2013). In this study, low collision 
and high collision energy MS data were separately analysed with XCMS and 
CAMERA in order to generate two independent peak lists. Using correlation 
analysis between the ion intensities of the low energy and the high energy 
peak list, the authors showed that precursor-fragment associations could be 
retrieved and the resulting spectra were highly similar to the results of a 
MS/MS experiment. In this thesis we described the development of the 
software tool cosmiq, which improves the detection of low abundant ion 
signals by combining multiple LCMS runs prior to peak detection. The 
implementation of the cosmiq peak detection pipeline in such a DIA 
workflow has the potential to increase the number of detected fragment ions 
and therefore would also improve the assignment of low abundant fragment 
ions to their potential precursors. Especially for the identification of fatty acyl 
chains in untargeted lipidomics, the relevant fragment intensities for lipids 
are very low (See Castro-Perez et al. 2010, Figure 7). In summary, the 
combination of our capillary LCMS methods and the software package 
cosmiq, in addition to a DIA workflow has the potential to further improve 
data interpretation of untargeted metabolomics and lipidomics experiments. 
An application example for the described analytical methods and the software 
package cosmiq (without DIA) was reported in the third chapter of this thesis. 
In a combined analysis of metabolomics, lipidomics and transcriptomics data 
we report an exploratory study of metabolic changes during colorectal cancer 
development. A basic finding was that in premalignant lesions and cancer 
tissue, many enzymes involved in central metabolism pathways were 
upregulated in addition to an increase of relevant metabolite within these 
pathways. Some of these enzymes were already known to be upregulated as 
part of metabolic reprogramming in cancer. Our data however suggest that a 
significant portion of metabolic reprogramming is already observable in 
premalignant lesions and therefore would explain an adaptation of 
proliferating cells in early stages of tumorigenesis. We also found metabolic 
alterations which were more prominent in cancer compared to the 
premalignant lesions. Among them is an increased amount of amino acids, an 
increased overexpression of SLC transporter for glucose and neutral amino 
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acids, and an increase in VLC-PUFA synthesis. As a general perspective, these 
exploratory data may serve as basis for deeper investigations of the observed 
alterations in colorectal cancer metabolism. One hypothesis we draw from 
this study is that pathways such as glycolysis and nucleotide synthesis are 
induced by an increase in enzyme activity in premalignant lesions and 
therefore early proliferating cells might have an activated anabolic 
metabolism for the synthesis of building blocks such as DNA, which is 
important for proliferation. However, several transporters for glucose and 
glutamine are only upregulated in cancer but not in adenomas. Glucose and 
glutamine are important fuels for the energetic and biosynthetic needs of the 
proliferating cells and we speculate that this increased uptake of glucose and 
glutamine might lead to a more aggressive proliferative phenotype of cancer. 
Future experiments might test this hypothesis, for example by generating two 
model systems, where the MYC gene and one or more of the cancer specific 
transporter genes such as SLC7A5, SLC2A3 or SLC2A1 are induced. Also, our 
data and methods might be used as the basis for biomarker discovery studies. 
It has already been shown that metabolites are altered in the urine or plasma 
of patients with cancer and can distinguish between healthy and diseased 
subjects with promising specificity and sensitivity (Farshidfar et al., 2012; Li et 
al., 2012; Manna et al., 2014). The development of adenoma specific 
biomarkers could be a clinical benefit for the early diagnosis of premalignant 
tumors. With the knowledge of the metabolic activities inside a tumor biopsy 
it is possible to make predictions about the alterations of metabolites which 
might be excreted from the tumor and are suspected to be found in body 
fluids. In addition to alterations in the metabolome it might be very helpful  
to consider the information about solute carrier transporter information into 
such predictions, especially those transporters which are important for the 
excretion of metabolites outside the cell. It is already known that cancer cells 
excrete lactate using the transporter MCT4 (Meijer et al., 2012). The 
knowledge about SLC overexpression and their relevant metabolite 
substrates, together with the observed alterations in the metabolome might 
help to generate hypotheses to find novel diagnostic opportunities to detect 
premalignant lesions in body fluids. 
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Appendix 
Table A- 1: Composition of internal standard mixtures. Each metabolite standard was dissolved in 
HPLC grade water. Each lipid standard was dissolved in 1:1 chloroform:methanol. Metabolite internal 
standards were obtained from Cortecnet, Voisins-Le-Bretonneux, France. Lipids were obtained from 
Avanti Polar Lipids (Alabaster, AL, USA). 
 
 
Table A- 2: Composition of 89 metabolite mixture used for the chracterization of stationary phases. 
Each compound in the mix has a concentration at 100 uM. 
 
 
Name Label Mass Concentration
Metabolites:
Isovaleric Acid-1-13C, 99% 13C 1 C13 103.03505 2 mM
SODIUM PYRUVATE-2-13C, 99% 13C 1 C13 89.0194 2 mM
Malonic Acid-13C3, 99% 13C All C13 107.021025 2 mM
Taurine-15N 1 N15 126.011701 2 mM
D-GLUCOSE-1-13C, 99% 13C 1 C13 181.066745 2 mM
D-Fructose-1-13C 1 C13 181.066745 2 mM
AMP-13C10,15N5, 98% 13C, 96-98% 15N 98% 13C, 96-98% 15N 362.081813 2 mM
Dimethyl succinate-2,2,3,3-d4 4 D 150.083018 2 mM
Sodium L-Lactate-1-13C solution, 99% 13C 1 C13 91.03505 2 mM
D-Sorbitol-1-13C 1 C13 183.082395 2 mM
UREA-15N2, 98% 15N All N15 62.026433 2 mM
Algal Amino Acid Mixture-13C-15N: 98% 13C, 98% 15N 2 mg/ml
Lipids:
1,2-diheptadecanoyl-sn -glycero-3-phospho-(1'-rac-glycerol) 772.523 1 mg/ml
1,2-diheptadecanoyl-sn -glycero-3-phosphoethanolamine 719.547 1 mg/ml
1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine 509.348 1 mg/ml
1,2-diheptadecanoyl-sn -glycero-3-phosphocholine 761.593 1 mg/ml
1,2,3-triheptadecanoyl-glycerol 848.78 1 mg/ml
Margaric acid 270.2559 1 mg/ml
2-Oxoglutarate / alphaKetoGlutarate Galactose Mannose
2,3 BisPhosphoGlycerate gamma-amino-butyricacid Methionine
3-methyl-2-oxobutyrate (KetoValin) Glucosamine-6-phosphate Mevalonolactone
3-methyl-2-oxovalerate (KetoIsoLeu) Glucose Myo inositol
3-Phosphoglycerate Glucose 1-phosphate N-acetyl-glucosamine
4-methyl-2-oxovalerate (KetoLeu) Glucose 6-phosphate N2-Acetyl Lysine
6-phosphogluconate Glucuronate Nicotinate
Adenine Glutamine Ornithine
Adenosine diphosphate Glycerate Oxaloacetate
Adenosine monophosphate Glycerol Pantothenate
Adenosine triphosphate Glycerol-phosphate Phenylalanine
Alanine Glycine Phenylpyruvate
alpha-amino-butyricacid Glyoxylate Phosphoenolpyruvate
Arginine Guanine Proline
Asparagine Guanosine diphosphate Pyruvate
Aspartate Guanosine monophosphate Ribose
Carbamoyl phosphate Guanosine triphosphate* Ribose 5-phosphate
Citrate Histidine Ribose-1-phosphate
cyclo-Adenosin monophosphate Homoserine Ribulose 5-phosphate
cyclo-Guanosine monophosphate Hydroxy-proline Serine
Cysteine iso-Citrate Shikimate
Cystine Isoleucine Succinate
Diamino-pimelate L-Glutamic acid Sucrose
Dihydroxyacetonephosphate L-Histidinol Threonine
Erythrose 4-phosphate L-Malate Trehalose
Fructose Lactate Tryptophane
Fructose 1-phosphat Leucine Tyrosine
Fructose 1,6-biphosphate Lysine V aline
Fructose 6-phosphate Maltose Xylose
Fumarate Mannitol
 99 
Table A- 3: List of 98 MYC target genes. This list was retrieved from Ji et al. (2011). 
 
Entrez:ID Gene Entrez:ID Gene Entrez:ID Gene Entrez:ID Gene Entrez:ID Gene
6723 SRM 4691 NCL 91942 NDUFA12L 6418 SET 81892 C14orf156
26135 SERBP1 51540 SCLY 55781 RIOK2 6838 SURF6 55055 ZWILCH
26135 SERBP1 6599 SMARCC1 51520 LARS 55847 ZCD1 51728 POLR3K
26135 SERBP1 26354 GNL3 10146 G3BP1 9188 DDX21 55720 TSR1
26135 SERBP1 26354 GNL3 10146 G3BP1 56652 PEO1 27043 PELP1
10885 WDR3 26354 GNL3 4869 NPM1 23082 PPRC1 5198 PFAS
7203 CCT3 8607 RUVBL1 4869 NPM1 9221 NOLC1 57003 CCDC47
7203 CCT3 6434 SFRS10 4869 NPM1 54663 WDR74 25926 NOL11
7203 CCT3 5471 PPAT 51491 HSPC111 7004 TEAD4 3609 ILF3
54865 GPATC4 10606 PAICS 7919 BAT1 7004 TEAD4 2091 FBL
54865 GPATC4 55153 SDAD1 7919 BAT1 7004 TEAD4 27338 UBE2S
1660 DHX9 3184 HNRPD 3326 HSP90AB1 58516 FAM60A 2618 GART
51514 DTL 3184 HNRPD 134637 DEADC1 1594 CYP27B1 2618 GART
57539 WDR35 3184 HNRPD 7532 YWHAG 4234 METTL1 23481 PES1
57539 WDR35 3184 HNRPD 54984 PINX1 4234 METTL1 4809 NHP2L1
64682 ANAPC1 9987 HNRPDL 25879 WDSOF1 29902 C12orf24 4809 NHP2L1
84172 POLR1B 54433 NOLA1 65083 NOL6 328 APEX1 92745 SLC38A5
79828 METTL8 54433 NOLA1 65083 NOL6 328 APEX1 1736 DKC1
84128 WDR75 79960 PHF17 55035 NOL8 328 APEX1
51602 NOP5/NOP58 6059 ABCE1 54107 POLE3 11198 SUPT16H
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Figure A- 1: Between group analysis (BGA) of colorectal adenoma metabolome based on different 
clinical parameters (a-f) as grouping information. Left panel shows the score plots of the BGA analysis 
and the loadings (metabolites) oft he same analysis are shown in the right panel. The red ellipse 
indicates the 99% percentile of randomly generated loadings after a permutation test (See materials and 
methods). Loadings outside the ellipse are considered as significant. 
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Figure A- 2: Expression values of selected genes based on the BGA classification (see Figure 3.2 c). The 
genes were randomly selected from the center of each classified group in the scatter plot: a) Up in P and 
CA, b) Down in P and CA, c) up in P, d) down in P, e) up in CA, f) down in CA. NM = normal mucosa, 
P = polyp, CA = cancer. The entrez gene name is shown. For each gene, a p-value was obtained by one-
way anova analysis using NM, P and CA as group information. 
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Figure A- 3: Pyrimidine metabolism pathway. The pathway map was generated from the KEGG kgml 
data files (Ogata et al., 1999) using cytoscape (Shannon et al., 2003). The annotation is the same as in 
Figure 3.6. The gene label is not displayed for the purpose of better visibility. 
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Figure A- 4: Purine metabolism pathway. This Figure was created as explained in Figure A-3. 
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Figure A- 5: Mapping of enzyme gene expression changes to KEGG pathway map “fatty acid 
metabolism”. Each arrow represents one reaction step. Bright green: not affected human gene. Blue: 
Deregulated in adenoma (P) and cancer (CA). Yellow: Deregulated in adenoma (P). Red: Deregulated in 
cancer (CA). a) Upregulated in PCA, b) downregulated in PCA, c) upregulated in P, d) downregulated 
in P, e) upregulated in CA, f) downregulated in CA.  
a) 
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Figure A- 5 (continued) 
b) 
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Figure A- 5 (continued) 
 
c) 
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Figure A- 5 (continued) 
 
d) 
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Figure A- 5 (continued) 
 
e) 
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Figure A- 5 (continued) 
  
f) 
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Figure A- 6: Workflow to select significant variables from different omics datasets based on BGA and a 
permutation test, demonstrated on an example transcriptomics dataset (Golub et al., 1999). a) Biplot of 
the BGA results are shown with loadings in black and scores in color (EWS=Ewing family of tumours, 
NB = neuroblastoma, RMS = rhabdomyosarcoma). b) loadings plot of the same dataset (black) and 
loadings of 100 permutations of this data. c) histogram of the vector length between origin and BGA 
Axis 1 and 2 of all permuted loadings. Black line indicates the 99% percentile of these vector lengths. d) 
scatter plot of the original data as seen in a) and b) in black, showing additionally the 99% percentile of 
the randomly permuted loading vector lengths as radius of a red circle. All the loadings inside this 
circle are considered as randomly generated with 99% confidence. 
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